Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

2014

Investigating the Role of the PGF2 Alpha/Calcineurin-Signaling
Pathway in the Regulation of Adipogenesis
Damodaran Annamalai
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Molecular Biology Commons

Recommended Citation
Annamalai, Damodaran, "Investigating the Role of the PGF2 Alpha/Calcineurin-Signaling Pathway in the
Regulation of Adipogenesis" (2014). Dissertations. 885.
https://ecommons.luc.edu/luc_diss/885

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2014 Damodaran Annamalai

LOYOLA UNIVERSITY CHICAGO

INVESTIGATING THE ROLE OF
THE PGF2α/CALCINEURIN-SIGNALING PATHWAY
IN THE REGULATION OF ADIPOGENESIS

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDANCY FOR THE DEGREE OF

DOCTOR OF PHILOSOPHY

PROGRAM IN MOLECULAR PHARMACOLOGY
AND THERAPEUTICS

BY
DAMODARAN ANNAMALAI
CHICAGO, ILLINOIS
MAY 2014

Copyright by Damodaran Annamalai, 2014
All rights reserved.

ACKNOWLEDGEMENTS
I am grateful to my mentor Dr. Neil Clipstone for his continuous support,
encouragement and excellent mentorship throughout the course of my graduate
education. I am thankful to him for accepting me into his lab, when I was in a difficult
situation and helping me to complete PhD. He was always available not only to answer
my scientific questions, but was also available to patiently listen and provide helpful
suggestions for my personal issues as well. He always encouraged and supported my
interest to combine my veterinary skills with research experience and to become a
laboratory animal veterinarian. It is a great honor to work under his guidance and I look
forward to his mentorship throughout my career.
I would like to thank my dissertation committee members, Dr. Tarun Patel,
Dr. Mitchell F. Denning, Dr. Adriano Marchese and Dr. Basabi Rana for their time,
support and directions during my committee meetings to shape this dissertation.
I thank Dawn Dike for her help and support during my rotation and during the
initial period of my research work in Dr. Clipstone’s lab. I am thankful to Lorraine
Grimsby, Leona Moore, Ellen Goodman, Donna Karl and Janet Flores for their help and
taking care of administrative hurdles.
I am grateful for my friends Veluswamy & Priya, Velmurugan & Sathya, Ravi
Sundaresan & Prabha, Saminathan & Vanji, Shankar & Suguna, Prassanna & Subha,

iii

Bharath & Theja and Anand who made my life enjoyable during my stay in Chicago. My
special thanks goes to Dr. Sethubathi who helped me in all the possible ways.
Finally, I want to thank my parents, Annamalai and Kuppmmal and my in-laws
Jayaraman and Kalaiarasi for their love and support. I am grateful for my wife, Lavanya
and my daughter, Govardhini for their support, affection and their patience to adjust with
my student life.

iv

To my beloved parents

Annamalai & Kuppammal

TABLE OF CONTENTS
ACKNOWLEDGEMENTS

iii

LIST OF TABLES

x

LIST OF FIGURES

xi

LIST OF ABBREVIATIONS

xiv

ABSTRACT

xix

CHAPTER I: INTRODUCTION
Epidemiology and sequela of obesity
Adipocytes and their physiological roles
Development of obesity and associated complications
Obesity, inflammation and impaired adipogenesis
Adipogenesis - An overview
Preadipocytes
Process of adipocyte differentiation
Initial growth arrest
Induction of adipocyte differentiation with hormonal stimuli
Mitotic clonal expansion
Terminal differentiation
Transcriptional regulation of adipogenesis
Early transcription factors - C/EBPβ and C/EBPδ
Early transcription factor - CREB
Proadipogenic transcription factor - C/EBPα
Proadipogenic transcription factor - PPARγ
Regulation of the PPARγ transcriptional activity
Role of PPARγ in adipogenesis
Extracellular factors regulating adipocyte differentiation
Prostaglandins
PGF2α - A potent inhibitor of adipogenesis
PGF2α synthesis, signaling and functions
Anti-adipogenic effects of PGF2α in cultured preadipocytes
Mechanisms of PGF2α-mediated inhibition of adipocyte
differentiation

1
1
2
3
4
6
6
7
8
8
10
12
12
13
16
16
18
19
20
21
22
24
24
25
26

vi

PGF2α inhibits adipogenesis through calcineurin-dependent signaling
Role of PGF2α in physiological inhibition of adipose tissue
development in vivo
Summary

28
29
30

CHAPTER II: MATERIALS AND METHODS
Cell culture and adipocyte differentiation
Plasmid constructs
Dominant-negative gp130
EpoR/gp130-WT, 1F and 4F
STAT1, IL-11 and CRTC2 specific shRNAs
MSCV-DsRed2-PPARγ2
Nurr1-WT, Nurr1-AA and Nurr1-KLL
Dominant-negative Nurr1
ER-caCRTC2
YFP-CRTC2
K-CREB and CREB R314A
Retroviral generation and infection of 3T3-L1 cells
Immunoblot analysis
Quantitative real-time PCR (qRT-PCR) analyses
Enzyme-linked immunosorbent assay (ELISA)
Immunofluorescence
Luciferase assay
Statistical analysis

32
32
33
33
33
34
35
35
36
37
38
38
39
39
40
41
41
42
43

CHAPTER III: THE PGF2α/CALCINEURIN-SIGNALING PATHWAY
INHIBITS ADIPOGENESIS VIA AN AUTOCRINE/PARACRINEMEDIATED IL-11/GP130/STAT1-DEPENDENT SIGNALING CASCADE
Introduction
Interleukin-11 (IL-11) cytokine
IL-11 signaling
Role of IL-11 in inhibiting adipogenesis
STAT transcription factors
Expression of STATs during adipogenesis
Role STAT3 in adipogenesis
Role of STAT1 in adipogenesis
Role of ERK in adipogenesis
Results
Activation of the PGF2α/calcineurin-signaling pathway induces the
expression of IL-11 in differentiating 3T3-L1 preadipocytes
IL-11 and gp130 cytokine co-receptor-dependent signaling play a role in
mediating the inhibitory effects of PGF2α on adipocyte differentiation
gp130 cytokine co-receptor-dependent signaling is sufficient to inhibit
adipocyte differentiation by blocking the expression of PPARγ

44

vii

44
45
46
46
49
49
50
51
51
52
52
56
65

C-terminal tyrosine residues involved in the activation of STAT
transcription factors play a critical role in mediating the inhibitory
effects of gp130 signaling on adipocyte differentiation
A critical role for STAT1 in mediating the inhibitory effects of gp130,
IL-11 and PGF2α on adipocyte differentiation
STAT1 depletion enhances the efficiency of adipocyte differentiation:
Evidence for an intrinsic negative regulatory role
Discussion

65

CHAPTER IV: THE PGF2α/CALCINEURIN-SIGNALING PATHWAY
UPREGULATES THE EXPRESSION OF THE ORPHAN NUCLEAR
HORMONE RECEPTOR NURR1 THROUGH A CRTC/CREBDEPENDENT MECHANISM: A POTENTIAL ROLE IN INHIBITING
ADIPOCYTE DIFFERENTIATION
Introduction
Nurr1 and its family members (NR4A Family)
Expression and functions of NR4A family members
Role of Nurr1 and its family members in adipogenesis
Structure and regulation of Nurr1 activity
Regulation of gene expression by Nurr1 and its family members
Regulation of Nurr1 expression by the calcineurin phosphatase and the
CRTC2/CREB transcriptional complex
CREB transcription factor
CRTC family of transcriptional co-activators
Results
The PGF2α/calcineurin-signaling pathway induces Nurr1 expression in
differentiating 3T3-L1 preadipocytes
Nurr1 plays a potential role in mediating the inhibitory effects of PGF2α
on adipocyte differentiation
Nurr1-mediated inhibition of adipogenesis requires its direct DNA
binding
Nurr1-mediated inhibition of adipogenesis does not require its
heterodimerization with RXR
CREB and its association with CRTC2 are required for PGF2α-mediated
Nurr1 expression during adipocyte differentiation
The PGF2α/calcineurin-signaling pathway induces the activation and
nuclear translocation of CRTC2 co-activator during adipogenesis
PGF2α requires the CRTC proteins to induce Nurr1 expression during
adipogenesis
CRTC2 activity is sufficient to induce Nurr1 expression and to inhibit
adipocyte differentiation
CRTC co-activator proteins play a critical role in the regulation of
normal adipocyte differentiation
Discussion

91

viii

69
79
82

91
91
91
92
93
96
96
97
98
101
101
104
107
111
111
114
117
120
123
127

CHAPTER V: SUMMARY AND CONCLUDING COMMENTS

136

REFERENCES

144

VITA

172

ix

LIST OF TABLES
Table
1.

Page
Nucleotide sequence of primers used for qRT-PCR

x

43

LIST OF FIGURES
Figure

Page

1.

Schematic model showing the adipocyte differentiation and the
sequential expression of adipogenic transcription factors

2.

Schematic model showing the PGF2α-mediated inhibition of adipocyte
differentiation via activation of the calcineurin phosphatase

27

3.

Schematic model showing the IL-11/gp130-dependent signaling
pathways

47

4.

PGF2α treatment of differentiating 3T3-L1 preadipocytes induces the
calcineurin-dependent expression and secretion of IL-11.

53

5.

gp130-dependent signaling play a role in mediating the inhibitory
effects of PGF2α on adipocyte differentiation.

57

6.

IL-11 play a role in mediating the inhibitory effects of PGF2α on
adipocyte differentiation.

60

7.

Schematic model illustrating the chimeric EpoR/gp30 receptors used in
this study.

63

8.

gp130-dependent signaling is sufficient to inhibit adipocyte
differentiation.

64

9.

Tyrosine residues involved in STAT transcription factor activation play
a role in mediating the inhibitory effects of gp130-dependent
signaling on adipocyte differentiation.

66

10.

gp130-dependent selective activation of STAT1, but not STAT3
inhibits adipocyte differentiation.

70

xi

9

11.

STAT1-depletion rescues adipocyte differentiation from the
EpoR/gp130-chimeric receptor signaling.

73

12.

STAT1-depletion rescues adipocyte differentiation from the IL-11
cytokine

75

13.

STAT1-depletion rescues adipocyte differentiation from PGF2α.

77

14.

STAT1-depletion enhances the efficiency of adipocyte differentiation
in response to suboptimal adipogenic stimulation.

80

15.

Schematic model illustrating the proposed mechanism by which
PGF2α inhibits adipogenesis.

89

16.

Schematic model showing the structure of Nurr1 and the modes of
regulation of gene expression by Nurr1

94

17.

Schematic model showing the activation of the CRTC2 co-activator

99

18.

The PGF2α/calcineurin-signaling pathway induces Nurr1 expression,
but not other family members during adipocyte differentiation

102

19.

Evidence that Nurr1 potentially plays a role in mediating the inhibitory
effects of PGF2α on adipogenesis

106

20.

Ectopic expression of Nurr1 inhibits adipogenesis via a DNA binding
and RxR-independent mechanism

109

21.

PGF2α induces Nurr1 expression through CREB-dependent
mechanism during adipogenesis

112

22.

The PGF2α/calcineurin-signaling pathway induces sustained activation
of CRTC2

115

23.

CRTC co-activators are required for the PGF2α to induce Nurr1
expression during adipocyte differentiation

118

24.

Conditional and selective activation of the constitutively active CRTC2
is sufficient to induce Nurr1 expression and to inhibit adipogenesis

121

25.

CRTC is required for normal adipocyte differentiation

125

26.

Schematic model showing that the PGF2α/calcineurin-signaling
pathway induces Nurr1 expression via CRTC2/CREB transcriptional

133

xii

complex to inhibit adipogenesis
27.

Schematic model showing the signaling pathways involved in
mediating the inhibitory effects of PGF2α on adipogenesis

xiii

142

LIST OF ABBREVIATIONS
AGIF

Adipogenesis inhibitory factor

Akr

Aldo-keto reductase

ANOVA

Analysis of variance

aP2

Adipocyte protein 2

Brdu

Bromodeoxyuridine

bZIP

Basic Leucine Zipper Domain

C/EBP

Ccaat-enhance-binding protein

CaMK

Calmodulin kinase

cAMP

Cyclic adenosine monophosphate

CBP

CREB binding protein

CDC

Center for Disease Control and Prevention

Cdc25c

Cell division cycle 25 homolog c

Cdc45I

Cell division cycle 45 homolog

CDK2

Cyclin-dependent kinase 2

ChIP

Chromatin immunoprecipitation

CLC

Cardiotrophin-like cytokine

CNTF

Ciliary neurotrophic factor

CoREAST

Co-repressor for element-1-silencing transcription factor

xiv

CRE

cAMP response element

CREB

cAMP response element-binding protein

CRTC

CREB-regulated transcription co-activator

CsA

Cyclosporin A

CsA

Cyclosporine

CT-1

Cardiotrophin-1

DEC1

Deleted in esophageal cancer 1

DN

Dominant-negative

DNA

Deoxyribonucleic acid

ELISA

Enzyme-linked immunosorbent assay

Epo

Erythropoietin

EpoR

Erythropoietin receptor

ER

Estrogen receptor

ERK

Extracellular signal-regulated kinase

GAS

Gamma activated sequence

GFP

Green fluorescence protein

Gins1

GINS complex subunit 1

GLUT4

Glucose transporter type 4

gp130

Glycoprotein 130

GPCR

G protein-coupled receptor

GSK-3β

Glycogen synthase kinase-3 beta

HDAC

Histone deacetylase
xv

HIF-1

Hypoxia-inducible factor-1

HPRT

Hypoxanthine phosphoribosyltransferase

IGF-1

Insulin-like growth factor 1

IL-11

Interleukin 11

IL-11Rα

IL-11 receptor alpha

IL-6

Interleukin 6

INFγ

Interferon gamma

JAK

Janus kinase

kdm4b

Lysine (K)-specific demethylase 4b

KRAB

Kruppel associated box

LIF

Leukemia inhibitory factor

LPL

Lipoprotein lipase

MAPK

Mitogen activated protein kinase

MCE

Mitotic clonal expansion

Mcm3

Mini-chromosome maintenance complex component 3

MDI

Methyl isobutyl xanthine, Dexamethasone, Insulin

MEF

Mouse embryonic fibroblast

NBRE

Nerve growth factor I-B response element

NCoR

Nuclear receptor co-repressor

NF-κB

Nuclear factor κB

NFAT

Nuclear factor of activated T cells

Nor 1

Neuron-derived orphan receptor 1
xvi

Nurr1

Nuclear receptor related 1

ORO

Oil Red O

OSM

Oncostatin M

PCR

polymerase chain reaction

PG

Prostaglandin

PGF2α

Prostaglandin F2 alpha

PKA

Protein kinase A

PKC

Protein kinase C

PPARγ

Peroxisome proliferator-activated receptor gamma

PREF-1

Preadipocyte factor-1

qRT-PCR

Quantitative real-time PCR

Rb

Retinoblastoma

RIP 140

Receptor interacting protein 140

RNA

Ribonucleic acid

RXR

Retinoid X receptor

SAMP6

P6 strain of senescence-accelerated mice

SCD1

Stearoyl-CoA desaturase 1

SDS

Sodium dodecyl sulfate

SIK

Salt inducible kinase

siRNA

small interfering RNA

SMRT

Silencing mediator for retinoid and thyroid receptor

STAT

Signal transducer and activator of transcription
xvii

TCF 4

Transcription factor 4

TFIID

Transcription factor II D

TNFα

Tumor necrosis factor alpha

WAT

White adipose tissue

WHO

World Health Organization

WT

Wild type

WT

Wild-type

YFP

Yellow fluorescence protein

xviii

ABSTRACT
Prostaglandin F2α (PGF2α) is a potent physiological inhibitor of adipocyte
differentiation, that has recently been shown to play an important role in the regulation of
adipose tissue development in vivo, where it acts to oppose the development of obesity
and its associated co-morbidities. Hence, it is of considerable interest to understand the
underlying molecular mechanisms by which PGF2α inhibits adipogenesis. In this respect,
previous studies from our laboratory have demonstrated that PGF2α inhibits
adipogenesis via activation of the calcium/calmodulin-regulated, serine/threonine
phosphatase, calcineurin. However, the precise molecular mechanism by which the
PGF2α/calcineurin-signaling pathway inhibits adipogenesis is not known. Accordingly,
the goal of this dissertation project was to identify the underlying molecular mechanisms
by which this pathway inhibits adipocyte differentiation. Since the best known function
of calcineurin is the regulation of gene expression, our central hypothesis was that
calcineurin activation induces the expression of a gene(s) directly responsible for
inhibiting adipogenesis. To test this hypothesis, we initially performed a microarray
analysis to identify candidate calcineurin-regulated genes likely to be responsible. As a
result of this analysis, we identified two excellent candidate genes that were strongly
induced by PGF2α in a calcineurin-dependent fashion: the IL-11 cytokine and the Nurr1
orphan nuclear hormone receptor. This dissertation describes our investigations into the

xix

potential roles of IL-11 and Nurr1 in mediating the inhibitory effects of the
PGF2α/calcineurin-signaling pathway on adipogenesis.
Initially, we demonstrate that activation of the PGF2α/calcineurin signaling
pathway in differentiating 3T3-L1 preadipocytes induces the expression and secretion of
IL-11. First, using a combined shRNA and dominant-negative mutant approach, we
provide evidence that IL-11 acts in an autocrine fashion via the gp130 cytokine
co-receptor signaling subunit to inhibit adipogenesis. Second, by taking advantage of a
well-characterized panel of chimeric gp130 receptor mutants, we demonstrate that the
activation of gp130-dependent signaling is sufficient to inhibit adipogenesis, and more
specifically, that the gp130-mediated activation of the STAT1 transcription factor is
necessary for this effect. Conversely, we find that the depletion of endogenous STAT1
rescues adipogenesis from the anti-adipogenic effects of both IL-11 and PGF2α.
Collectively, our findings support a model in which PGF2α inhibits adipocyte
differentiation by establishing a calcineurin-dependent, IL-11-mediated autocrine
negative feedback loop, that acts via gp130 to block adipogenesis through the essential
actions of the STAT1 transcription factor.
In addition to IL-11, we find that Nurr1, an orphan nuclear hormone
receptor, is also highly upregulated by the PGF2α/calcineurin-signaling pathway during
the early stages of adipogenesis. Using a panel of CREB transcription factor mutants and
a shRNA knockdown approach, we show that the CREB transcription factor and more
specifically, its association with members of the CREB-regulated transcriptional coactivator (CRTC) family of proteins is required for PGF2α to induce Nurr1 expression.
xx

Furthermore, using a conditionally active CRTC2 mutant, we demonstrate that activation
of CRTC proteins is sufficient to both induce Nurr1 expression and inhibit adipocyte
differentiation. Finally, using a dominant-negative approach, we provide evidence that
Nurr1 is involved in mediating the inhibitory effects of PGF2α on adipogenesis. Further,
using Nurr1 mutants that are either deficient in their ability to bind DNA or
heterodimerize with RxR, we demonstrate that Nurr1 requires its direct DNA binding
activity, but not its interaction with RxR to inhibit adipogenesis. Taken together, these
results demonstrate that, in addition to the IL-11 cytokine, the PGF2α/calcineurinsignaling pathway also activates a CRTC/CREB/Nurr1-dependent signaling cascade to
inhibit adipocyte differentiation.
In summary, my studies have helped to identify and delineate two independent
signaling pathways that function downstream of calcineurin to mediate the inhibitory
effects

of

PGF2α

on

adipogenesis:

the

IL-11/gp130/STAT1-

and

the

CRTC/CREB/Nurr1-signaling pathways. Thus, the current findings of this dissertation
project provide significant new insights into the molecular mechanisms by which the
PGF2α/calcineurin-signaling pathway acts to inhibit adipocyte differentiation.

xxi

CHAPTER I
INTRODUCTION
1. Epidemiology and sequela of obesity: Obesity, an excessive accumulation of adipose
tissue, is a major public health problem and is emerging as a worldwide epidemic in both
developed and developing countries. The Centers for Disease Control and Prevention
(CDC) report that about one-third of USA adults (34.9%) are already obese in 2012,
while childhood obesity is increasing at an alarming rate with 18% children in USA aged
between 6 and 11 years being classified as obese (Ogden, 2013). Further, the World
Health Organization (WHO) reports that obesity has doubled worldwide since 1980 and
about 500 million adults worldwide are currently obese (WHO, 2013). Obesity is a major
risk factor for the development of several co-morbidities such as insulin resistance, type 2
diabetes, coronary artery disease, hypertension, hyperlipidemia and several cancers (De
Pergola and Silvestris, 2013; Kahn and Flier, 2000; Kahn et al., 2006; Nakamura et al.,
2013; Van Gaal et al., 2006). These obesity-associated diseases are linked to reduced life
expectancy and premature death (Olshansky et al., 2005). Hence, it is important to
understand the development of adipose tissue and obesity at the molecular level in order
to identify better therapeutic targets to treat obesity and its associated complications.

1

2
2. Adipocytes and their physiological roles: Adipose tissue is primarily comprised of
specialized, lipid-storing cells called adipocytes. These specialized cells are
evolutionarily developed to store excess energy in the form of triglycerides during
abundant availability of food and to release energy in response to starvation and flight or
fight (Rosen and Spiegelman, 2006; Spiegelman and Flier, 2001). In addition to this
important role in energy homeostasis, adipocytes also perform an important endocrine
function and secrete a variety of biologically active molecules such as leptin, adiponectin,
resistin, TNFα, IL-6, angiotensinogen, fatty acids and others (Fruhbeck et al., 2001;
Kershaw and Flier, 2004; Vazquez-Vela et al., 2008; Waki and Tontonoz, 2007).
Collectively, these molecules are called adipokines and are known to regulate a variety of
functions including food intake, insulin responsiveness, cardiovascular function, vascular
remodeling and the immune response (Trujillo and Scherer, 2006; Vazquez-Vela et al.,
2008; Waki and Tontonoz, 2007). Importantly, leptin secreted predominantly by
adipocytes acts on the feeding center in the hypothalamus and inhibits appetite and food
intake (Friedman and Halaas, 1998). In fact, the ob/ob mouse that is deficient in leptin
and the db/db mouse that has a defective leptin receptor develop obesity at a very early
age and are used as models to study obesity and type 2 diabetes (Chen et al., 1996;
Coleman, 1978; Drel et al., 2006). In addition, adiponectin secreted by adipocytes
increase the insulin sensitivity, whereas resistin, IL-6 and TNFα are shown to induce
insulin resistance (Trujillo and Scherer, 2006). Thus, adipokines regulate whole body
metabolism by regulating food intake and insulin sensitivity. Collectively, adipocytes
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regulate energy homeostasis through storage and release of excess energy, and whole
body metabolism by secreting a variety of adipokines.

3. Development of obesity and associated complications: Adipocytes contribute to the
development of adipose tissue mass by two mechanisms: 1) an increase in the size of
adipocytes (hypertrophy) due to storage of energy as triglycerides, and 2) an increase in
the number of adipocytes (hyperplasia) due to de novo generation of adipocytes known as
adipogenesis (Hirsch and Batchelor, 1976; Spalding et al., 2008). Both adipocyte
hyperplasia and hypertrophy play a crucial role in the development of obesity. Adipocyte
hyperplasia plays a critical role in setting the number of adipocytes during early stages of
childhood development and the number then stays constant into adulthood. This initial
hyperplasia determines the degree of adipose tissue cellularity and subsequent propensity
to develop obesity in adulthood (Brook et al., 1972; Hirsch and Batchelor, 1976; Knittle
et al., 1979; Prins and O'Rahilly, 1997). In the adult, in the settings of positive energy
balance, adipocyte hypertrophy through excessive accumulation of triglycerides
contributes to the excessive accumulation of adipose tissue mass resulting in the
formation of large, lipid-filled, dysfunctional, hypertrophic adipocytes (Hoffstedt et al.,
2010; Krotkiewski et al., 1983; Weyer et al., 2000). These large dysfunctional
hypertrophic adipocytes eventually become unable to store any additional energy. As
long as new, small insulin-sensitive adipocytes are generated from the precursor cells
through adipogenesis, the excess energy can be stored by these new cells (Gray and
Vidal-Puig, 2007; Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). However,
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this essential adipogenic process is inhibited in extreme obesity by inflammatory
mediators as discussed later in this chapter. In the absence of new adipocytes, the excess
energy can be “spilled-over” and deposited as fat in non-adipose tissues such as liver,
skeletal muscle, heart muscles, pancreatic islets and the perivascular tissues. Since these
tissues are not specialized to store lipids, this can result in lipotoxicity in these tissues
leading to tissue dysfunction such as insulin resistance and inability to secrete insulin
(Gray and Vidal-Puig, 2007; Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). In
fact, transplantation of intact functional adipose tissue into both a lipodystrophy mouse
model (Gavrilova et al., 2000; Moitra et al., 1998) and a leptin deficient obese mouse
model with severe metabolic abnormalities (Sennello et al., 2006) resulted in
improvement in overall metabolic profile and insulin sensitivity. This shows that the lack
of functional adipose tissue capable of storing excess energy contributes to the
development of metabolic abnormalities in obesity. In addition, the large dysfunctional
adipocytes begin to secrete a more pathological array of adipokines such as resistin,
TNFα and IL-6 that are known to induce insulin resistance (Qatanani and Lazar, 2007).
Collectively, impaired adipogenesis leading to lipotoxicity to non-adipose tissues and
pathological array of adipokines secreted by dysfunctional adipocytes contribute to the
development of obesity associated complications such as insulin resistance and type 2
diabetes.

4. Obesity, inflammation and impaired adipogenesis: Though the total number of
adipocytes remains constant in adulthood, about 10% of the adipocytes are renewed
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annually throughout life (Spalding et al., 2008). The newly generated small insulinsensitive adipocytes are essential as they store excess energy and prevent lipid spill-over
to non-adipose tissues (Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). Thus,
adipogenesis increases the overall lipid buffering capacity of adipose tissue and prevents
lipotoxicity to non-adipose tissues. However, obesity is considered as an inflammatory
condition and a variety of inflammatory cells such as macrophages, T lymphocytes, B
lymphocytes, natural killer cells and neutrophils are recruited into adipose tissue (Cildir
et al., 2013; Nishimura et al., 2009; Talukdar et al., 2012; Weisberg et al., 2003; Winer et
al., 2011; Xu et al., 2003). These inflammatory cells produce a variety of inflammatory
mediators such as IL-6 and TNFα, which create a low-grade chronic inflammatory
condition in adipose tissue (Chawla et al., 2011; Gregor and Hotamisligil, 2011). In
addition, the large dysfunctional adipocytes in obesity also secrete various inflammatory
mediators (Qatanani and Lazar, 2007). These inflammatory mediators are known to
potently inhibit the differentiation of preadipocytes into mature adipocytes (Gustafson
and Smith, 2006; Xu et al., 1999). In fact, several line of evidence show that adipogenesis
is impaired in obese patients. The number of preadipocytes that undergo differentiation is
decreased in obese patients (Isakson et al., 2009) and these patients show a decreased
number of committed preadipocytes (Tchoukalova et al., 2007). Further, the expression
of genes involved in adipogenesis is decreased in type 2 diabetic patients (Dubois et al.,
2006). Collectively, this evidence shows that preadipocytes from obese individuals have
impaired potential to differentiate into adipocytes. In the absence of new insulin-sensitive
adipocytes, the lipid buffering capacity of adipose tissue is lost, resulting in lipid spill
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over, lipotoxicity and subsequent development of type 2 diabetes (Tan and Vidal-Puig,
2008; Virtue and Vidal-Puig, 2010). The direct link between obesity, inflammation and
diabetes is evident from the finding that the obese mouse model that lacks the expression
of TNFα shows enhanced insulin sensitivity and glucose homeostasis (Uysal et al.,
1997). Given the potential role of the inflammatory mediators in inhibiting adipogenesis,
it is important to understand the molecular mechanisms by which they inhibit
adipogenesis to identify better therapeutic targets to block this inhibitory effect on
adipogenesis and consequently, to treat the obesity-associated complications such as type
2 diabetes.

5. Adipogenesis - An overview: Adipogenesis is a highly complex, multistep process
that involves the initial commitment of multipotent stem cells into the adipogenic lineage
and subsequent terminal differentiation into mature adipocytes. Cell culture systems are
widely used to understand the adipocyte differentiation and they faithfully recapitulate
the in vivo adipogenic process (Armani et al., 2010).

5.1 Preadipocytes: Much of our current understanding about the molecular mechanisms
of adipocyte differentiation comes from studies using preadipocyte cell culture systems
(Rosen and MacDougald, 2006). Preadipocytes are cells committed to the adipocyte
lineage and have lost their potential to differentiate into other cell types. Both primary
preadipocytes and established preadipocyte cell lines are used to study adipocyte
differentiation (Green and Meuth, 1974; Gregoire et al., 1990; Nougues et al., 1988).
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Primary preadipocytes are derived from the vascular stromal fraction of adipose tissue.
These primary preadipocytes can be induced to differentiate into mature adipocytes with
a combination of adipogenic factors such as dexamethasone, insulin and 3-isobutyl-1methylxanthine (Armani et al., 2010). However, these primary cells cannot be cultured
for prolonged periods and do not maintain the differentiation state for extended periods of
time (Otto and Lane, 2005). In contrast, immortalized preadipocyte cell lines such as
3T3-L1 and 3T3-F442A were developed from non-clonal Swiss 3T3-L1 cells by Green
and associates in the 1970s and can be induced to differentiate into mature adipocytes
(Green and Meuth, 1974; Green and Kehinde, 1975; Green and Kehinde, 1976). These
two cell lines recapitulate much of the key features of adipogenesis in vivo such as
morphological changes, expression of lipogenic enzymes, extensive lipid accumulation
and sensitivity to key hormones that have effects on this cell type. In fact, subcutaneous
implantation of 3T3-F442A cells into mice can form functional adipose tissue (Green and
Kehinde, 1979). Therefore, the 3T3-L1 and 3T3-F422A cell lines provide a perfect model
to study adipocyte differentiation in vitro.

5.2 Process of adipocyte differentiation: The differentiation of preadipocytes into
mature, lipid-filled adipocytes is a multistep process which includes initial growth arrest,
mitotic clonal expansion and terminal differentiation into mature adipocytes (Gregoire et
al., 1998). The differentiation process is regulated by a sequential expression of
transcription factors including C/EBP family members and PPARγ. In this transcriptional
cascade, C/EBPβ and C/EBPδ are expressed within few hours of induction of
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adipogenesis, whereas C/EBPα and PPARγ are expressed later and then, they
coordinately induce the expression of adipocyte specific genes (Figure 1) (Rosen and
MacDougald, 2006).

5.3 Initial growth arrest: In the preadipocyte cell culture system, growth arrest is a
prerequisite for the differentiation of preadipocytes into mature adipocytes. The initial
growth arrest is achieved in cultured cell lines after contact inhibition and the cells arrest
at the G0/G1 cell cycle boundary (Patel and Lane, 2000). However, absolute cell-cell
contact is not required as confluent 3T3-F442A cells shifted to methylcellulose-stabilized
suspension culture still differentiate into adipocytes (Pairault and Green, 1979). Hence,
growth arrest, but not cell-cell contact, is required for preadipocytes to differentiate into
adipocytes.

5.4 Induction of adipocyte differentiation with hormonal stimuli: Growth-arrested,
post-confluent preadipocytes can be induced to terminally differentiate into mature, lipdfilled, morphologically distinct adipocytes with a hormonal cocktail that consists of
3-isobutyl-1-Methylxanthine, Dexamethasone and pharmacological concentrations of
Insulin or insulin-like growth factor 1 (IGF-1) in the presence of fetal bovine serum
(Rosen and Spiegelman, 2000; Schmidt et al., 1990). This hormonal cocktail is referred
as MDI. Mechanistically, 3-isobutyl-1-methylxanthine inhibits cAMP phosphodiestrase
and transiently increases intracellular cAMP concentration, which results in the activation
of protein kinase A (PKA) and subsequent activation of the downstream signaling
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FIGURE 1. Schematic model showing the adipocyte differentiation and
the sequential expression of adipogenic transcription factors.

Upon stimulation with the adipogenic cocktail MDI, two-day post confluent 3T3-L1
preadipocytes differentiate into mature adipocytes in 6 to 8 days after stimulation. During
the differentiation process, C/EBPβ and C/EBPδ are expressed within a few hours after
the induction of adipogenesis. Once expressed, C/EBPβ and C/EBPδ bind to the C/EBPα
and PPARγ promoters and induce their expression. Then, C/EBPα and PPARγ reinforce
each other’s expression and induce adipocyte specific genes to confer the adipocyte
phenotype.
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pathways such as the cAMP response element-binding protein (CREB) transcription
factor (Rosen and Spiegelman, 2000). CREB has been shown to regulate adipogenesis at
multiple stages (Fox et al., 2008; Reusch et al., 2000; Zhang et al., 2004a) and is
discussed later in this chapter. Dexamethasone is a glucocorticoid and is known to
activate cytoplasmic, nuclear hormone, glucocorticoid receptors. It has been show to
induce the expression of the early transcription factor, C/EBPδ (Cao et al., 1991). Insulin
increases the percentage of cells that differentiate into mature adipocytes (Girard et al.,
1994). Although preadipocytes express few insulin receptors (Reed and Lane, 1980), the
pharmacological concentration of insulin has been shown to cross-activate IGF-1 receptor
signaling during adipogeneic induction (Smith et al., 1988). The activation of the insulin
and IGF-1 receptors results in the activation of multiple signaling pathways that regulate
adipogenic process. Thus, the hormonal cocktail MDI along with fetal bovine serum
potently induces the preadipocytes to differentiate into mature adipocytes.

5.5 Mitotic clonal expansion: When the post-confluent, growth-arrested preadipocytes
in G0/G1 phase are stimulated with MDI, they synchronously re-enter the cell cycle and
undergo two or three rounds of cell division, known as mitotic clonal expansion (MCE)
(Cornelius et al., 1994; Tang et al., 2003b). The synchronous entry of growth-arrested
preadipocytes into S phase is evidenced by changes in the cell cycle regulatory proteins
such as expression and activation of cdk2-cyclin-E/A, down regulation of p27/kip1,
hyperphosphorylation of Rb, translocation of cyclin D1 from the nuclei to cytoplasm and
GSK-3β from cytoplasm to nuclei and incorporation of [3H] thymidine into DNA (Tang
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et al., 2003b). The MCE is an important step for the differentiation of cultured
preadipocytes into mature adipocytes. In fact, inhibiting cell cycle progression with
rapamycin (Yeh et al., 1995a) or aphidicolin (Reichert and Eick, 1999) inhibits
adiopocyte differentiation. Collectively, these findings indicate that mitotic clonal
expansion plays a critical role in adipocyte differentiation.
During the MCE process, DNA replication and epigenetic modifications in the
chromatin structure at regulatory sequences increase the accessibility of critical ciselements to transactivating factors, which activate or de-repress the expression of genes
required for terminal differentiation into mature adipocytes (Musri et al., 2010). For
example, initial studies showed that the SWI/SNF chromatin remodeling enzyme
complex promotes transcription of PPARγ gene by C/EBPβ (Salma et al., 2004). In the
case of the C/EBPα promoter, HDAC1 blocks its expression, but once PPARγ protein
accumulates, it is able to target HDAC1 to proteasome degradation and allows activation
of C/EBPα expression (Zuo et al., 2006). A recent study using DNase I Hypersensitive
site analysis to identify open chromatin regions during adipogenesis showed that major
chromatin remodeling events occur within the first 4 h of adipogenesis and one third of
PPARγ target hotspots are primed for subsequent PPARγ binding by 4 h of adipogenic
stimulation (Siersbaek et al., 2011). Further, the histone hyperacetylation associated with
gene expression is selectively increased at the promoter regions of adipogenic genes,
whereas the expression of several histone deacetylases and the deacetylase enzyme
activity associated with gene repression are decreased during adipocyte differentiation
(Yoo et al., 2006). Collectively, chromatin remodeling that occurs during MCE leads to
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adipocyte specific gene transcription and subsequent terminal differentiation into mature
adipocytes.

5.6 Terminal differentiation: After 2 or 3 rounds of MCE, cells withdraw from the cell
cycle, enter into permanent growth-arrest and terminally differentiate into mature
adipocytes over 6 to 8 days after adipogenic stimulation. During this stage, the cells
express adipocyte specific genes like aP2, GLUT4, leptin, adiponectin and others.
Subsequently, the preadipocytes acquire biochemical and morphological characteristics
of mature adipocytes through de novo lipogenesis and accumulation of fat droplets,
thereby acquiring a spherical, lipid filled morphology. In addition, the differentiated cells
also acquire insulin sensitivity and respond to hormones that are known to act on
adipocytes in vivo (Gregoire et al., 1998).

6. Transcriptional regulation of adipogenesis: Adipocyte differentiation is regulated by
a sequential and orchestrated expression of transcription factors. Several transcription
factors involved in this process have been identified. However, C/EBPs and PPARγ are
considered as critical transcription factors that determine the terminal differentiation of
adipocytes (Farmer, 2006). In this transcriptional cascade, C/EBPβ and C/EBPδ are
expressed within a few hours of induction of adipogenesis (Cao et al., 1991; Yeh et al.,
1995b). Once expressed, C/EBPβ and C/EBPδ coordinately bind to C/EBPα and PPARγ
gene promoters and induce their expression. Once expressed, C/EBPα and PPARγ are
able to bind to each other’s promoter and serve to reinforce each other’s expression via
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positive feedback loop, thus ensuring their persistent expression in mature adipocytes
(Rosen et al., 2002; Wu et al., 1996). More importantly, C/EBPα and PPARγ
coordinately bind to the promoter of adipocyte specific genes and induce their expression
to confer adipocyte phenotype (Tontonoz et al., 1994).

6.1 Early transcription factors - C/EBPβ and C/EBPδ: C/EBPβ and C/EBPδ are
basic-leucine zipper family of transcription factors that are rapidly expressed within 4 h
of induction of adipocyte differentiation and are referred to as the early transcription
factors of adipogenesis (Cao et al., 1991; Yeh et al., 1995b). The role of C/EBPβ, but not
C/EBPδ, in adipogenesis has been extensively studied.
Upon exposure to MDI, C/EBPβ expression is induced by methylisobutyxanthine
which acts via CREB, whereas C/EBPδ expression is induced by dexamethasone (Cao et
al., 1991; MacDougald et al., 1994; Zhang et al., 2004a). Further, CREB and its family
members have been shown to bind to the proximal promoter of C/EBPβ and induce its
expression within 4 h of adipogenic stimulation. Once expressed, C/EBPβ is
phosphorylated by MAPK on Thr-188 between 2 to 4 h after induction and the
phosphorylated C/EBPβ translocates into the nucleus (Tang et al., 2005), where this
phosphorylation is sustained by cdk2 throughout the MCE phase (Li et al., 2007). Within
the nucleus, C/EBPβ is further phosphorylated by GSK3β on Thr-179 or Ser-184 (Tang
et al., 2005). These sequential phosphorylation events cause a conformational change that
allows homodimerization and acquisition of DNA binding ability by C/EBPβ between 12
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and 16 h after the induction of differentiation (Tang and Lane, 1999). In fact, C/EBPβ has
been shown to bind to centromeric satellite DNA during this time period and the DNA
binding activity coincides with the entry of cells into S phase of the cell cycle (Tang and
Lane, 1999). After gaining DNA binding ability, C/EBPβ induces expression of cell
cycle specific genes such as Cdc45I (cell division cycle 45 homolog), Mcm3 (minichromosome maintenance complex component 3), Gins1 (GINS complex subunit 1),
Cdc25c (cell division cycle 25 homolog c) and Mcm3 histone demathylase during MCE
(Guo et al., 2012). C/EBPβ also induces the expression of epigenetic modifiers kdm4b, a
histone demethylase (Guo et al., 2012), and G9a, a histone dimethylase during MCE (Li
et al., 2013). Once induced, kdm4b acts as a co-activator of C/EBPβ to induce the
expression of cell cycle specific genes, whereas G9a dimethylates the proximal promoters
of PPARγ and C/EBPα, and inhibits their expression until the cells exit the cell cycle
(Guo et al., 2012; Li et al., 2013). These findings clearly demonstrate that C/EBPβ plays
a crucial role in the regulation of MCE and progression of the adipogenic process.
The important role of C/EBPβ in adipocyte differentiation is evident from the
finding that the mouse embryonic fibroblasts (MEFs) from C/EBPβ knockout mice fail to
differentiate into adipocytes due to their inability to undergo MCE. In contrast,
overexpression of C/EBPβ in these cells restores their capacity to differentiate into
adipocytes (Tang et al., 2003a). The importance of C/EBPβ is further supported by the
finding that a dominant-negative form of C/EBPβ, which prevents the nuclear
translocation and DNA binding activity of endogenous C/EBPβ, inhibits differentiation
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by blocking the MCE process (Zhang et al., 2004b). Interestingly, ectopic expression of
C/EBPβ in the 3T3-L1 cells induces them to undergo adipogenesis without exogenous
adipogenic stimuli (Yeh et al., 1995b), and overexpression of C/EBPβ induces the
multipotent NIH-3T3 cell line to differentiate into adipocytes (Wu et al., 1995),
suggesting that C/EBPβ is sufficient to induce adipogenesis in certain settings. In the in
vivo setting, C/EBPβ knockout mice show a slight reduction in adipose tissue mass
compare to their wild type counter parts, whereas C/EBPδ knockout mice develop with
normal amounts of adipose tissue. Conversely, in C/EBPβ and C/EBPδ double knockout
mice, 85% of the animals die on day 1 after birth and the remaining mice survive, but
show a dramatic reduction in adipose tissue mass and the expression of adipocyte specific
genes (Tanaka et al., 1997). This shows that C/EBPβ and C/EBPδ transcription factors
complement each other and play a critical role in the development of adipose tissue.
In addition to the critical role of C/EBPβ and C/EBPδ proteins in the MCE, these
proteins also regulate terminal differentiation by inducing C/EBPα and PPARγ
expression. C/EBPα and PPARγ possess functional C/EBP binding sites in their
promoters and are induced by C/EBP proteins (Christy et al., 1991; Clarke et al., 1997;
Wu et al., 1996). Specifically, ectopic expression of C/EBPβ alone, or in combination
with C/EBPδ in NIH 3T3-L1 cell line induces PPARγ expression and converts these cells
into adipocytes (Wu et al., 1996).
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6.2 Early transcription factor - cAMP responsive element binding protein (CREB):
CREB is constitutively expressed in preadipocytes and is phosphorylated upon addition
of adipogenic cocktail by signaling pathways initiated by methylisobutylxanthine and
insulin through PKA and ERK signaling, respectively (Klemm et al., 1998; Martini et al.,
2009; Reusch et al., 2000). The important role of CREB in adipogenesis is evident from
the findings that the activation of a constitutively active CREB is sufficient to induce
adipogenesis in the absence of adipogenic cocktail, whereas either dominant-negative
CREB or siRNA-mediated knockdown of CREB inhibits adipogenesis (Fox et al., 2006;
Reusch et al., 2000). Indeed, CREB binds to the C/EBPβ promoter along with its family
members and induces its expression (Fox et al., 2006; Niehof et al., 1997; Zhang et al.,
2004a). It also induces expression of cyclin D1 during the early stages of adipogenesis,
which is required for the MCE process (Fox et al., 2008). Further, CREB directly binds to
the PPARγ2 promoter and induces its expression (Fox et al., 2006). In addition, CREB
also binds to the promoters of several other adipocyte-specific genes (Reusch et al.,
2000). Collectively, CREB plays an important role in adipogenesis by regulating the
expression of multiple adipogenic genes.

6.3 Proadipogenic transcription factor - C/EBPα: When preadipocytes are induced to
differentiate with the adipogenic cocktail, C/EBPα is expressed after 2 days of induction
(Cao et al., 1991; Yeh et al., 1995b). The early transcription factors C/EBPβ and C/EBPδ
directly bind to the consensus binding sites in the proximal promoter of C/EBPα and
induce its expression (Cao et al., 1991). Once expressed, C/EBPα binds to the promoter
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of the adipocyte specific genes such as aP2, GLUT4 and SCD1, and transactivates their
expression (Christy et al., 1989; Kaestner et al., 1990). Collectively, this results in
terminal differentiation into mature adipocytes. In addition, C/EBPα is also an antimitotic factor and stimulates the cells to exit MCE by inducing the expression of cell
cycle inhibitor, p21 and by increasing its stability (Harris et al., 2001; Timchenko et al.,
1996). Further, C/EBPα inhibits cdk2 activity by directly interacting with p21 and cdk2,
thereby preventing cell cycle progression (Harris et al., 2001). Thus, C/EBPα regulates
adipogenesis by inhibiting MCE and inducing the expression of adipocyte specific genes.
The important role of C/EBPα in adipocyte differentiation is evident from the loss
and gain of function experiments in preadipocyte cell lines. The expression of antisense
C/EBPα RNA in 3T3-L1 cells inhibits adipogenesis and prevents the expression of
several adipocyte specific genes (Lin and Lane, 1992), whereas expression of C/EBPα in
preadipocytes and mouse fibroblasts induces these cells to differentiate into adipocytes
without the addition of adipogenic stimuli (Freytag et al., 1994; Lin and Lane, 1994).
These results suggest that C/EBPα is both necessary and sufficient to induce
adipogenesis. The crucial in vivo role of C/EBPα in adipose tissue development is
evident from the analysis of C/EBPα knockout mice, as these mice die within a few
hours after birth due to impairment of hepatic gluconeogenesis (Wang et al., 1995).
Interestingly, these mice survived with selective expression of C/EBPα in liver, but failed
to develop white adipose tissue, except in the mammary fat pat (Linhart et al., 2001).
Further, replacement of C/EBPα with C/EBPβ in a mouse model results in decreased
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development of white adipose tissue compared to its wild type litter mates (Chen et al.,
2000). Collectively, these findings show that C/EBPα plays a critical role in the
adipocyte differentiation and the development of adipose tissue in vivo.
In addition to its role in adipocyte differentiation and the expression of adipocyte
specific genes, C/EBPα plays a crucial role in the insulin sensitivity of adipocytes. In
fact, fibroblasts from C/EBPα null mice express low levels of PPARγ and fail to
differentiate into mature adipocytes. While these cells differentiate into adipocytes with
ectopic expression of PPARγ, these adipocytes show a complete absence of insulinstimulated glucose transport due to decreased expression and tyrosine phosphorylation of
the insulin receptor and it downstream signaling protein, IRS-1 (Wu et al., 1999). This
shows that C/EBPα specifically induces genes involved in the insulin sensitivity of
mature adipocytes.

6.4 Proadipogenic transcription factor - PPARγ: PPARγ belongs to the nuclearreceptor superfamily of ligand-activated transcription factors (Feige et al., 2006) and is
expressed as two isoforms, PPARγ1 and PPARγ2 from the same gene through alternative
splicing and promoter usage (Zhu et al., 1995). Though PPARγ1 and PPARγ2 are
expressed in adipocytes, PPARγ1 is expressed ubiquitously, whereas PPARγ2 expression
is exclusively restricted in adipocytes (Vidal-Puig et al., 1996). PPARγ induces gene
expression by binding to the promoter of its target genes at consensus nuclear hormone
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binding sites as a heterodimer with its nuclear binding partner, retinoid X receptor (RXR)
(Palmer et al., 1995).

6.4.1 Regulation of the PPARγ transcriptional activity: PPARγ is a ligand-activated
transcription factor and while several lipid metabolites including polyunsaturated fatty
acids, prostanoids, prostaglandin 15 deoxy -∆12, 14- prostgandin J2 are considered as
putative ligands for PPARγ, an endogenous ligand that potently activates PPARγ has not
yet been identified (Tontonoz and Spiegelman, 2008). Interestingly, PPARγ is the target
for antidiabetic thiazolidinedione drugs (Lehmann et al., 1995) and these drugs are shown
to increase adipocyte differentiation in vitro (Kletzien et al., 1992; Sandouk et al., 1993)
and increase adipose tissue mass in vivo (Hallakou et al., 1997).
In addition to its ligands, PPARγ activity is also regulated by several co-activators
and co-repressors. In the absence of a ligand, PPARγ binds to NCoR (nuclear receptor
co-repressor) and SMRT (silencing mediator for retinoid and thyroid receptor)
transcriptional co-repressors (Guan et al., 2005), resulting in the inhibition of its
transcriptional activity, whereas blocking the expression of both NCoR and SMRT by
siRNA in 3T3-L1 cells results in their more efficient differentiation into adipocytes (Yu
et al., 2005). Another co-repressor called receptor interacting protein 140 (RIP 140) has
also been shown to inhibit PPARγ transcriptional activity (Debevec et al., 2007). Upon
binding to a ligand, the co-repressor complex associated with PPARγ is replaced by coactivators, resulting in the gene transcription (Perissi and Rosenfeld, 2005). Several
transcriptional co-activators including CBP/p300, steroid receptor coactivators and
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TRAP200/DRIP205 are known to directly interact with PPARγ and induce its
transcriptional activity (Powell et al., 2007). In addition, several post translational
modifications are known to regulate the transcriptional activity of PPARγ. The
phosphorylation of PPARγ at S112 induced by ERK activation inhibits the transcriptional
activity of PPARγ and blocks adipogenesis (Camp and Tafuri, 1997; Hu et al., 1996).
Further, sumoylation of PPARγ at K107 inhibits its transcriptional activity (Ohshima et
al., 2004; Yamashita et al., 2004). In addition, PPARγ is poly ubiquitinated and degraded
by the proteasome (Floyd and Stephens, 2002; Hauser et al., 2000). Thus, it is clear that
the PPARγ activity is regulated by multiple mechanisms, including multiple coactivators, co-repressors and post translational modifications.

6.4.2 Role of PPARγ in adipogenesis: During the adipogenic process PPARγ is
expressed after 2 days of induction and its expression is induced by the early transcription
factors C/EBPβ and C/EBPδ (Christy et al., 1991; Clarke et al., 1997; Wu et al., 1995).
The delayed expression of PPARγ is important due to its anti-mitotic activity, which
induces the cells to exit the cell cycle and undergo permanent growth-arrest (Altiok et al.,
1997). Once expressed, the more important function of PPARγ is to induce the expression
of genes involved in lipogenesis and insulin sensitivity to confer the adipocyte phenotype
(Rosen et al., 2000). Most adipocyte specific genes contain PPARγ binding sites and are
shown to be regulated by PPARγ. A recent study with genome-wide ChIP-seq profiling
of PPARγ:RxR-binding sites in differentiating 3T3-L1 cells demonstrated that the
PPARγ:RxR heterodimer binds to more than 5000 gene promoters, with the majority of
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the genes involved in glucose and lipid metabolism (Nielsen et al., 2008). In addition,
PPARγ also induces the expression of C/EBPα. Thus, a positive feed-back loop exists
between PPARγ and C/EBPα to reinforce each other expression and to maintain their
expression in the mature adipocytes (Otto and Lane, 2005; Rosen et al., 2002).
Multiple evidence show that PPARγ is the master regulator of adipogenesis and
the failure of expression of PPARγ prevents adipogenesis. In fact, the ectopic expression
of PPARγ induces fibroblasts to express adipocyte specific genes without adipogenic
stimuli and subsequently, these cells accumulate triglycerides (Tontonoz et al., 1994). In
contrast, embryonic stem cells that lack PPARγ fail to differentiate into adipocytes
(Rosen et al., 1999). Interestingly, PPARγ can induce adipogenesis in C/EBPα deficient
MEF, whereas C/EBPα cannot induce adipogenesis in the absence of PPARγ (Rosen et
al., 2002). This shows that PPARγ alone is sufficient to induce adipogenesis. Though
germline PPARγ deficiency is embryonic lethal (Barak et al., 1999), selective depletion
of PPARγ2 in a mouse model resulted in decreased white adipose tissue mass and
decreased insulin sensitivity (Rosen et al., 1999). Collectively, both in vitro and in vivo
studies show that PPARγ is both sufficient and necessary for adipogenesis and is the
master regulator of adipocyte differentiation.

7. Extracellular factors regulating adipocyte differentiation: The efficiency of
adipocyte differentiation both in vitro and in vivo is strongly influenced by the
environmental milieu, with a fine balance of extracellular factors that positively and
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negatively regulate the adipogenic process (MacDougald and Mandrup, 2002). The
extracellular factors regulate adipogenesis through activation of multiple signaling
pathways that ultimately induce or inhibit the expression of the above mentioned key
adipogenic transcription factors. Various factors including several hormones, cytokines,
growth factors and some pharmacological compounds are known to positively regulate
adipogenesis (MacDougald and Mandrup, 2002). For example, insulin and IGF-1 are
potent inducers of adipogenesis and are required for complete differentiation of
preadipocytes into mature adipocytes (Girard et al., 1994; Smith et al., 1988). In contrast,
several factors including Wnt, epidermal growth factor, resistin, PREF-1 and proinflammatory cytokines TNFα, IL-6 and IL-11 are known to inhibit adipogenesis by
blocking the expression of key adipogenic transcription factors (MacDougald and
Mandrup, 2002). For example, Wnts, a family of secreted proteins, are considered as
potent inhibitors of adipocyte differentiation. Interestingly, inhibition of Wnt signaling
using a dominant-negative form of its downstream signaling protein TCF4 in 3T3-L1
cells induces these cells to spontaneously differentiate into adipocytes in the absence of
adipogenic stimuli (Bennett et al., 2002; Ross et al., 2000). Another important class of
agents that are known to influence adipocyte differentiation both positively and
negatively is the prostaglandins which are discussed below.

7.1 Prostaglandins: Prostaglandins (PGs) are a group of lipid mediators and are
synthesized through a series of enzymatic process from membrane phospholipids. First,
arachidonic acid is liberated from membrane phospholipids by phospholipase A2. Then,
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it is converted to PGH2, a common precursor of all PGs, by cyclooxygenase enzymes.
Finally, PGH2 is metabolized to various PGs such as PGD2, PGE2, PGF2α, PGI2 and
thromboxane A2 by the action of specific PG synthases (Breyer et al., 2001; Ricciotti and
FitzGerald, 2011). After biosynthesis, prostaglandins are rapidly transported out of the
cell and act in an autocrine and paracrine manner on their cognate PG receptors that
belong to the membrane spanning G-protein couple receptors (Breyer et al., 2001;
Ricciotti and FitzGerald, 2011). Though PGs are known to play an important role in
mediating inflammation, they also regulate several cellular processes including adipocyte
differentiation. Specific PGs have been shown to either promote or inhibit adipocyte
differentiation. PGI and PGD2 metabolite PGJ2 have been shown to have a positive
effect on adipocyte differentiation (Forman et al., 1995; Reginato et al., 1998). PGI
promotes adipogenesis by inducing the expression of early transcription factors C/EBPβ
and C/EBPδ through a cAMP-dependent mechanism (Aubert et al., 2000), while PGD2
metabolite 15-deoxy-∆12, 14-prostaglandine J2 has been shown to potently induce
adipocyte differentiation, possibly through its role as a putative endogenous ligand of
PPARγ (Forman et al., 1995). In contrast, PGE2 and PGF2α are known as inhibitors of
adipocyte differentiation (Inazumi et al., 2011; Serrero et al., 1992; Tsuboi et al., 2004).
PGE2 and a selective agonist of EP receptor inhibit adipocyte differentiation by blocking
the expression of PPARγ, whereas an EP receptor antagonist promotes adipocyte
differentiation (Tsuboi et al., 2004). More importantly, PGF2α is a potent physiological
inhibitor adipogenesis (Volat et al., 2012) and is discussed below.
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7.2 PGF2α - A potent inhibitor of adipogenesis:
7.2.1 PGF2α synthesis, signaling and functions: PGF2α is synthesized, as described
earlier, from arachidonic acid by a series of enzymatic reactions. The terminal enzymes
that catalyze the conversion of PGH2 to PGF2α are aldo-keto reductases (Akrs). Though
several tissue specific isoforms of Akrs are expressed, Akr1b7 and Akr1b3 are highly
expressed in preadipocytes and act as PGF2α synthases in these cells (Fujimori et al.,
2010b; Tirard et al., 2007). When Akr1b7 expression was depleted in a mouse model,
these mice showed a significantly decreased level of PGF2α in their adipose tissue,
which shows that Akr1b7 plays a critical role in the PGF2α synthesis in vivo (Volat et al.,
2012). Once synthesized and released, PGF2α binds and activates a specific Gαq coupled
GPCR called the FP prostanoid receptor (Breyer et al., 2001; Narumiya et al., 1999).
Activation of the FP receptor results in the stimulation of phospholipase C, an increase in
intracellular calcium and the subsequent activation of several downstream signaling
pathways including phosphotidylinositol-3 kinase, protein kinase C, mitogen-activated
protein kinases, tyrosine kinases and stimulation of the Rho small G-protein and the
activation of the β-catenin/TCF-signaling pathway (Breyer et al., 2001; Fujino and
Regan, 2001; Pierce et al., 1999; Watanabe et al., 1994; Watanabe et al., 1995). The
PGF2α-mediated signaling pathways have been shown to regulate various biological
processes including bone remodeling, reproduction, inflammation, and vascular and
endometrial remodeling (Agas et al., 2013; Ricciotti and FitzGerald, 2011). Importantly,
PGF2α has been shown to potently inhibit adipocyte differentiation both in vitro and in
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vivo (Casimir et al., 1996; Lepak and Serrero, 1993; Serrero et al., 1992; Volat et al.,
2012).

7.2.2 Anti-adipogenic effect of PGF2α in cultured preadipocytes: Initial studies
showed that arachidonic acid, the precursor of prostaglandins, inhibits adipocyte
differentiation and the pretreatment with cyclooxygenase inhibitors block this inhibitory
effect (Casimir et al., 1996). This showed that the prostaglandins synthesized from
arachidonic acid inhibit adipogenesis. Further, prostaglandins F2α, E2 and D2 were able
to mimic the inhibitory effect of arachidonic acid when added to the adipogenic cocktail.
Among these prostaglandins, PGF2α is the most effective and highly potent in inhibiting
adipocyte differentiation (Casimir et al., 1996). More importantly, PGF2α is produced by
preadipocytes themselves and its production is highest in dividing nonconfluent cells. But
its level dropped by approximately 70% after stimulation and the level remained at low
throughout the differentiation process (Miller et al., 1996). This shows that PGF2α seems
to act as a negative regulator of adipocyte differentiation. Further, the activation of the
cognate PGF2α receptor (FP receptor) with a selective agonist, fluprostenol inhibits
preadipocytes differentiation, whereas FP receptor antagonists prevents the inhibitory
effects of fluprostenol on adipogenesis (Casimir et al., 1996; Miller et al., 1996). This
confirms that the activation of FP receptor inhibits adipogenesis. FP receptors are present
throughout differentiation, as the membranes prepared from either 3T3-L1 preadipocytes
or adipocytes exhibits specific binding for PGF2α (Miller et al., 1996). Given the fact
that endogenous PGF2α production decreases during the differentiation and the FP
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receptors present throughout the differentiation process, the FP-receptor mediated
inhibition of adipogenesis appears to be regulated by the alteration in the PGF2α
concentration rather than the receptor expression (Miller et al., 1996). In addition, when
several prostaglandins were examined, structurally similar prostaglandin 9 alpha, 11 betaPGF2α potently inhibited adipogenesis, suggesting that the structural characteristics of
PGF2α is required for its inhibitory effect on adipogenesis (Lepak and Serrero, 1993).

7.2.3 Mechanisms of PGF2α-mediated inhibition of adipocyte differentiation:
Several mechanisms have been proposed for the inhibitory effects of PGF2α on
adipogenesis. Initial studies showed that the activation of FP receptor with fluprostenol
transiently increases the intracellular calcium and a calcium/calmodulin-dependent
protein kinase inhibitor rescues the inhibitory effect (Miller et al., 1996). This study
suggested that the PGF2α-induced increase in intracellular calcium inhibits adipogenesis
by activation of the calcium-dependent downstream signaling pathways. Similarly, a
number of studies have shown that increases in intracellular calcium concentration during
the early phase of human and 3T3-L1 preadipocyte differentiation act to potently inhibit
adipogenesis (Neal and Clipstone, 2002; Ntambi and Takova, 1996; Shi et al., 2000).
Further, PGF2α-mediated activation of ERK has been linked to the inhibition of
adipogenesis by causing an inhibitory phosphorylation of PPARγ (Reginato et al., 1998).
In addition, PGF2α has been shown to inhibit adipogenesis through upregulation of HIF1 transcription factor under normoxic condition (Liu and Clipstone, 2008). HIF-1 induces
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FIGURE 2. Schematic model showing the PGF2α-mediated inhibition of adipocyte
differentiation via activation of the calcineurin phosphatase.

PGF2α activates Gαq coupled G-protein coupled receptor and increases the intracellular
concentration of Ca2+. The increased intracellular Ca2+ activates calcium-dependent
phosphatase, calcineurin. The PGF2α/calcineurin-signaling pathway inhibits adipocyte
differentiation by blocking the expression of late transcription factors (C/EBPα and
PPARγ), but the early transcription factors (C/EBPβ and C/EBPδ) are not affected.
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the expression of a HDAC associated transcriptional repressor DEC1, which has been
shown to directly repress the PPARγ promoter. Interestingly, trichostatin A, an HDAC
inhibitor rescues differentiation from PGF2α, suggesting the role of a HDAC regulated
gene, possibly DEC1 in mediating the inhibitory effects of PGF2α on adipogenesis (Liu
and Clipstone, 2008). More importantly, studies from our laboratory have shown that
PGF2α inhibits adipogenesis through a calcium-dependent phosphatase calcineurin (Liu
and Clipstone, 2007), which is discussed below.

7.2.4 PGF2α inhibits adipogenesis through calcineurin-dependent signaling: Initial
studies from our laboratory showed that calcineurin activity is required for the inhibitory
effects of calcium ionophore, as the presence of the calcineurin inhibitors either CsA or
FK506, rescued differentiation from the inhibitory effect of calcium inophore on
adipogenesis (Neal and Clipstone, 2002). In addition, ectopic expression of a calciumindependent, constitutively active calcineurin inhibited differentiation of 3T3-L1 cells
into adipocytes (Neal and Clipstone, 2002). Collectively, these findings show that
calcineurin activity inhibits adipocyte differentiation. Later, studies from our laboratory
showed that the calcineurin phosphatase acts as a potent downstream effector in
mediating the inhibitory effects of PGF2α (Liu and Clipstone, 2007). In fact, PGF2α
requires Gαq, but not Gβγ subunits of G-protein to inhibit adipocyte differentiation (Liu
and Clipstone, 2007). The activation of Gαq is well known to activate phospholipase C,
which results in a subsequent increase in intracellular calcium (Katritch et al., 2013).

29
When the 3T3-L1 cells are induced to differentiate in the presence of PGF2α along with
an inhibitor of receptor-mediated plasma membrane Ca2+-influx or a membrane
permeable Ca2+-chelator, both inhibitors rescue adipocyte differentiation, suggesting that
PGF2α-induced increase in intracellular calcium is responsible for the inhibition of
adipogenesis (Liu and Clipstone, 2007). It is also well known that the activity of
calcineurin phosphatase is regulated by intracellular calcium and calcineurin acts as a
negative regulator of adipocyte differentiation (Neal and Clipstone, 2002). Interestingly,
pretreatment with either a calcineurin inhibitor, cyclsporin A or FK506 or expression of a
calcineurin inhibitory VIVIT peptide completely rescues adipocyte differentiation from
the PGF2α-mediated inhibitory effect, suggesting that PGF2α acts through calcineurin
phosphatase to inhibit adipogenesis. Interestingly, PGF2α does not prevent the mitotic
clonal expansion during adipogenesis as well as expression of early transcription factors
C/EBPβ and C/EBPδ, whereas the expression of key adipogenic factors C/EBPα and
PPARγ is inhibited by PGF2α (Figure 2) (Liu and Clipstone, 2007). However, the precise
molecular mechanism by which the PGF2α/calcineurin-signaling pathway inhibits
adipogenesis by blocking the C/EBPα and PPARγ expression is not known.

7.2.5 Role of PGF2α in physiological inhibition of adipose tissue development
in vivo: A recent study using Akr1b7 knockout mice shows that PGF2α plays a critical
negative regulatory role in the development of adipose tissue in vivo (Volat et al., 2012).
As mentioned earlier, Akr1b7 is a terminal enzyme involved in the biosynthesis of
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PGF2α from its precursor PGH2 and is highly expressed in adipocyte precursor cells.
Further, its expression is down regulated during adipocyte differentiation, whereas
overexpression of Akr1b7 inhibits differentiation process of 3T3-L1 preadipocytes.
Interestingly, Akr1b7 knockout mice showed a significantly decreased level of PGF2α in
adipose tissue compared to wild type littermates and an increase in basal white adipose
tissue mass under normal feeding condition. Under a high fat diet, these animals rapidly
gained weight with a five-fold increase in plasma leptin level compared to their wild type
counterparts and developed insulin resistance. In contrast, daily administration of a
synthetic PGF2α, cloprostenol for 3 months to Akr1b7-/- mice resulted in a significant
decrease in plasma leptin level, which indicates a reduced white adipose tissue mass.
Further, BrdU treatment to asses adipose tissue expansion in high fat diet fed Akr1b7-/mice showed a 3.5 fold increase in BrdU-positive adipocyte-associated nuclei in gonadal
WAT from Akr1b7-/- compared with wild type, whereas cloprostanol treatment reduced
the production of new adipocytes under this condition to the level of WT mice fed with
HF-diet (Volat et al., 2012). This suggests that PGF2α inhibits adipocyte differentiation
and the generation of new adipocytes. Collectively, it is evident that PGF2α acts as a
physiological inhibitor of adipose tissue development in vivo. Hence, it will be interesting
to decipher the underlying molecular mechanisms involved in mediating the inhibitory
effects of PGF2α on adipocyte differentiation.

8. Summary: Adipocyte differentiation is a highly complex, well regulated cellular
process that is influenced by several positive and negative exogenous factors. One such
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factor that is known to potently inhibit adipogenesis both in vitro and in vivo is PGF2α.
Previous studies from our laboratory have shown that PGF2α acts through calciumdependent phosphatase, calcineurin to inhibit adipocyte differentiation. However, the
precise molecular mechanism by which the PGF2α/calcineurin-signaling pathway
inhibits adipogenesis is not known. In this dissertation project, we have explored the
underlying molecular mechanisms involved in mediating the inhibitory effects of PGF2α
on adipogenesis and found that IL-11, an IL-6 cytokine family member and Nurr1, an
orphan nuclear receptor are strongly induced by the PGF2α/calcineurin-signaling
pathway and play a role in mediating its inhibitory effects on adipocyte differentiation.
We have further explored the underlying mechanisms by which IL-11 and Nurr1 act to
inhibit adipogenesis and have delineated the pathways and mechanisms involved.
Collectively, our studies have afforded significant new insights into the mechanism by
which the physiologically relevant anti-adipogenic factor PGF2α acts to inhibit the
adipogenic process.

CHAPTER II
MATERIALS AND METHODS
1. Cell culture and adipocyte differentiation: The 3T3-L1 preadipocyte cells were
plated at the concentration of 8x104 cells per well of a 6-well plate and were grown to
confluence in DMEM/high glucose media (HyClone) supplemented with 10% fetal
bovine serum (Atlanta Biologicals). After 2 days, the confluent cells were treated for 48 h
with growth media plus the adipogenic cocktail, MDI (0.5 mM Methylisobutylxanthine,
1 µM Dexamethasone, and 10 µg/ml Insulin; all from Sigma). Cells were re-fed with
growth media containing 10 µg/ml insulin at day 2 and every 2 days thereafter with
growth media alone. Where indicated, cells were also treated for the first 48 h of the
induction period with the indicated concentrations of PGF2α (Calbiochem), 1 µg/ml
cyclosporin A (Calbiochem), recombinant murine IL-11 (50 ng/ml; Peprotech) and
recombinant mouse erythropoietin (40 ng/ml; BD Pharmingen). In some experiments,
conditioned media collected from 3T3-L1 cells ectopically expressing cDNAs encoding
either murine IL-11 or murine erythropoietin were used instead of recombinant cytokines
with identical results. To assess the extent of adipocyte differentiation, cells were fixed
on day 8 post-stimulation with 10% formalin for 60 min at 4°C, then after two washes
with phosphate buffered saline (PBS), were stained with filtered Oil Red O solution
(Sigma) for 2 hrs at room temperature. After staining, the cells were washed with PBS to
remove unbound dye and the plates were scanned. Cells were then counter stained with
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hematoxylin (Sigma) for 4 min and, after washing with PBS, were visualized by light
microscopy and photographed (40X).

2. Plasmid constructs:
2.1 Dominant-negative gp130: The dominant-negative version of gp130 (DN-gp130)
was generated by using a murine gp130 cDNA (Open Biosystems; clone I.D. 6834623)
as a template in a polymerase chain reaction (PCR) using PfuTurbo (Stratagene) together
with gene-specific primers designed to delete the C-terminal 213 amino acids containing
conserved amino acid residues known to be essential for gp130-mediated signaling
events (Taga and Kishimoto, 1997) and replacing them with a FLAG epitope tag
followed by a stop codon. The resulting DN-gp130 construct was then subsequently
introduced into the MSCV-GFP retroviral expression vector.

2.2 EpoR/gp130-WT, 1F and 4F: The wild-type EpoR/gp130 chimera and
corresponding mutant chimeras containing tyrosine-to-phenylalanine substitutions in
conserved residues of the gp130 cytoplasmic domain were kind gifts of Dr. Fred Schaper,
RWTH Aachen, Germany (Schaper et al., 1998; Schmitz et al., 2000). The wild type
EpoR/gp130 chimera was PCR-amplified using gene-specific primers and the resulting
PCR product was digested with SalI and MfeI, and introduced into the XhoI/EcoRI site
of the MSCV-GFP retroviral vector, giving rise to MSCV-EG-WT. To generate MSCVEG-1F and MSCV-EG-4F, Nsi I/Bam HI fragments corresponding to the C-terminal
region of murine gp130 containing either a Y759F single substitution (1F), or
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Y767F/Y814F/Y905F/Y915F quadruple substitutions (4F) were introduced into Nsi
I/Bam HI-digested MSCV-EG-WT backbone. The EpoR/gp130-4F “add back” mutants
were generated using PCR cloning techniques to fuse peptide sequences previously
reported to selectively activate either STAT1 (PTPSFGYDKPHV), or STAT3
(PTPSFGYFKQHV) (Gerhartz et al., 1996), in-frame with the extreme C-terminus of
EG-4F. Briefly, EG-4F was used as a template in a PCR reaction with the forward primer
5’-CTTCA TGCAT GTCAT CTTCT AGGC-3’ together with either 5’-AGGAT CCTAC
ACGTG TGGCT TGTCG TATCC GAAGG ATGTT GGCGT CTGTG GTAAG
AAACT TTTAG GC-3’ or 5’-GAGGA TCCTA CACGT GCTGC TTGAA GTATC
CGAAG GATGT TGGCG TCTGT GGTAA GAAAC TTTTA GGC-3’ as reverse
primers. The resulting PCR products were digested with Nsi I/Bam HI and introduced
into the corresponding sites of MSCV-EG-4F giving rise to EG-4F-STAT1 and EG-4FSTAT3, respectively.

2.3 STAT1, IL-11 and CRTC2 specific shRNAs: To generate retroviral constructs
capable of expressing shRNAs specific for STAT1, plasmids encoding STAT1-specific
shRNAs in the lentiviral vector pLKO.1 were purchased from Open Biosystems (Clone
I.D. TRCN0000054924 and TRCN0000054927) and used as templates in a PCR reaction
together with the forward primer 5’-CTCTC AATTG TATCG ATCAC GAGAC
TAGCC TC-3’; and the reverse primer 5’-CCTCA AGCTT GGATG AATAC TGCCA
TTTGT CTCG-3’. The resulting PCR fragments were digested with Mfe I and Hind III
and cloned into the pSR-GFP/Neo vector (OligoEngine) previously digested with Eco RI
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and Hind III to generate pSR-STAT1-924 and pSR-STAT1-927, respectively. The
shRNA retroviral constructs specific for murine IL-11 and murine CRTC2 were
generated by the identical approach using plasmids encoding IL-11 (Open Biosystems;
Clone

I.D.

TRCN0000066459)

and

CRTC2

(Open

Biosystems;

Clone

I.D.

TRCN00000176098)-specific shRNAs in the lentiviral vector pLKO.1. The control
shRNA retroviral vector specific for firefly luciferase has been described previously (Liu
and Clipstone, 2008).

2.4 MSCV-DsRed2-PPARγ2: The MSCV-DsRed2-PPARγ2 construct was generated by
isolating a blunted Afl III/Xba I fragment of the full-length murine PPARγ2 cDNA from
pSVSport-PPARγ2 (Addgene) and introducing it into MSCV-DsRed2 at the blunted
EcoRI site.

2.5 Nurr1-WT, Nurr1-AA and Nurr1-KLL: Plasmids encoding the murine wild type
Nurr1 (Nurr1-WT), the DNA binding defective Nurr1-C280A/E281A (Nurr1-AA), and
the RxR binding-defective Nurr1-K554A/L555A/L556A (Nurr1-KLL) in the pCMX
expression vector were kindly provided by Dr. Thomas Perlmann (Ludwig Institute for
Cancer Research, Karolinska Institute, Stockholm, Sweden). To generate a FLAG-tagged
version of WT-Nurr1, the pCMX-wtNurr1 plasmid was used in a polymerase chain
reaction using PfuTurbo (Stratagene) and 5’- CTCAGA TCTGAG ACCATG GACTAC
AAGGAC GACGAT GACAAG ATGCCT TGTGTT CAGGCG CAGTAT GG - 3’ as a
forward primer together with 5’- CTCGAT CATATG CGTAGT GGCCAC GTAGTT
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CTG - 3’ as a reverse primer. The resulting PCR product encoding the FLAG peptide
fused in-frame with the 5’ end of the wtNurr1 sequence was digested with Bgl II and Nde
I, then ligated into the Bgl II/Xho I-digested pMSCV-GFP retroviral expression vector
together with an Nde I/Xho I fragment encompassing the 3’ end of the wtNurr1 cDNA
isolated from pCMX-wtNurr1. FLAG-tagged versions of Nurr1-KLL and Nurr1-AA
were constructed in a similar manner using Nde I/Xho I fragments isolated from pCMXNurr1-KLL and pCMX-Nurr1-AA, respectively.

2.6 Dominant-negative Nurr1: The dominant-negative Nurr1 (DN-Nurr1) construct is
comprised of Nurr1 amino acids

from 94 to 365, lacking both N- and C-terminal

transactivation domains, fused in-frame with the N-terminal 100 amino acids of the ZPF10 KRAB family member containing the KRAB transcriptional repressor domain. First,
an Ndelta94-Nurr1 construct lacking the N-terminal 94 amino acids of Nurr1 was
generated by using the pCMX-wtNurr1 plasmid in a PCR reaction with 5’- TCTGAG
ACCATG TTCTAC CCATAC GACGTC CCAGAC TACGCT GTAGAA GACATT
CAGATG CAC - 3’ as the forward primer and 5’ -CTCGAT CATATG CGTAGT
GGCCAC GTAGTT CTG - 3’ as a reverse primer. The resulting PCR product was
digested with Bgl II and Nde I and ligated together with an Nde I/Xho I fragment
encompassing the 3’ end of the wtNurr1 cDNA isolated from pCMX-wtNurr1 into Bgl
II/Xho I-digested MSCV-GFP to give the MSCV-Ndelta94Nurr1 construct. Second, the
ZPF-10 plasmid (Open Biosystems) was used in a polymerase chain reaction together
with 5’- ACAGGA TCCCTC TCCCCC CTCACC TCCGGT GAGTCT GATCAT
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GGATGC TAAGTC ACTAAC TGCCTG GTC - 3’ as a forward and 5’ - GAGCTC
GAGTTA AACTGA TGATTT GATTTC AAATGC AG - 3’ as a reverse primer. The
resulting 400 bp fragment encompassing the amino acids 343-365 of Nurrr1 fused in
frame with the N-terminal 100 amino acids of ZPF-10 containing the KRAB
transcriptional repressor domain was digested with Bam HI and Xho I and ligated
together with a 1477 bp Spe I/Bam HI fragment from MSCV-Ndelta94Nurr1 comprising
amino acids 94-365 of Nurr1 into the MSCV-GFP vector digested with Spe I and Xho I.

2.7 ER-caCRTC2: To insert wild type FLAG-tagged murine CRTC2 into the MSCVGFP retroviral expression vector, the pcDNA3-FLAG-TORC2 construct (Addgene) was
used in a PCR reaction together with 5’ - CTCAGA TCTACC ATGGAC TACAAG
GACGAC GATGA C - 3’as the forward primer and 5’ - GAGCTC GAGTCA TTGGAG
CCGGTC ACTGCG GAATGA CTCC - 3’ as the reverse primer. The resulting PCR
fragment was digested with Bgl II and Xho I and ligated into Bgl II/Xho I-digested
MSCV-GFP.
The constitutively active CRTC2 mutant containing serine to alanine substitution
at amino acids 171 and 275 was generated using the mutagenic primers 5’ - CACTTA
ACAGGA CAAGCG CTGACT CTGCTC TTCAC - 3’ and 5’ - AACACA GGAGGC
GCCCTA CCTGAC C - 3’ together with the QuickChange II site-directed mutagenesis
kit from Stratagene. The tamoxifen-regulated conditionally active CRTC2 mutant was
created by first performing a PCR reaction with a plasmid encoding the tamoxifenregulated mutant version of murine estrogen receptor as template and 5’ - CTCGGA
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TCCACC ATGGAC TACAAG GACGAC GATGAC AAGCTG CAGGAT CCATCT
GCTGGA GACATG AGGGCT GC - 3’ as forward primer and 5’ - GAGGAA TTCGAT
CGTGTT GGGAAG CCCTC TGCT - 3’ as the reverse primer. The resulting 900 bp
fragment was digested with Bam HI and Eco RI and ligated into Spe I/Eco RI-digested
MSCV-caCRTC2 together with a 700 bp Spe I-Bgl II fragment from MSCV-GFP.

2.8 YFP-CRTC2: To generate an YFP-CRTC2 construct, pEYFP-C1 was used as a
template in a PCR reaction with 5’ - CTCAGA TCTGCC ACCATG GTGAGC
AAGGGC GAGGAG CTG - 3’ as forward primer and 5’ - GAGGAA TTCGGA
TCCGAG TCCGGA CTTGTA CAGCTC GTCCATG - 3’ as reverse primer. The
resulting 729 bp fragment was digested with Bgl II and Eco RI and ligated together with
an Eco RI/Xho I-digested 2152 bp fragment of wtCRCT2 into Bgl II/Sal I-digested
MSCV-GFP.

2.9 K-CREB and CREB R314A: To generate MSCV-CREB, a plasmid encoding rat
CREB (kind gift from Dr. Basabi Rana, Loyola University Chicago) was used as a
template in a PCR reaction together with 5’ - CTCCTC GAGACC ATGACC ATGGAC
TCTGGA GCAGAC AACCAG - 3’ as a forward primer and 5’ - GAGGAA TTCTTA
ATCTGA CTTGTG GCAGTA AAGGTC - 3’ as reverse primer and the resulting 1034
bp PCR fragment was digested with Xho I and Eco RI and ligated into Xho I/Eco RIdigested MSCV-GFP. The dominant-negative K-CREB mutant was generated by PCR
mutagenesis using the primers 5’- GCAAGA GAATGT CTTATA AAGAAG AAAG -
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3’ and 5’ - CTTTCT TCTTTA TAAGAC ATTCTC TTGC - 3’ together with the primers
listed above to introduce the R288L/R289I substitutions into the wtCREB sequence.
CREB-R314A was generated by a similar strategy using the primers 5’ - GAAAGA
ATATGT GAAATG TTTAGA GAACGC AGTGGC AGTGCT TG - 3’ and 5’ CAAGCA CTGCCA CTGCGT TCTCTA AACATT TCACAT ATTCTT TC - 3’.

The integrity of all constructs was confirmed by DNA sequence analysis.

3. Retroviral generation and infection of 3T3-L1 cells: Retroviral expression vectors
were co-transfected with pVSV-G (Clontech) into the GP293 pantropic packaging cell
line (Clontech) using Lipofectamine Plus (Invitrogen). Media was replaced after 24 h and
viral supernatants were collected after 24 h and 48 h post-transfection and stored
at -80ºC. For retroviral infections, 5x104 3T3-L1 cells were plated per well of a 6-well
plate, the next day media was replaced with retroviral particle-containing growth media
supplemented with 8 µg/ml polybrene (Sigma) and the plates were centrifuged in a
swinging bucket rotor at 1,000 rpm for 90 min at room temperature, then returned to the
incubator overnight. After 24 h, cells were subjected to a second round of infection,
essentially as described above, then expanded in regular growth medium prior to seeding
for subsequent experiments.

4. Immunoblot analysis: Whole cell lysates were prepared by adding boiling SDS
sample buffer (120 mM Tris-HCl pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol)
directly to cells on the plate. The cell lysates were collected by scraping and boiled for 10
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min, then sonicated for 10s using a Digital sonifier (Branson) at an amplitude of 11% and
stored at -80° C. An equal amount of protein from each treatment was resolved by SDSPAGE gel electrophoresis, transferred to nitrocellulose membrane, and subjected to
immunoblot analysis with the following primary antibodies: anti-STAT1 (#9172), antiphospho-STAT1 (Tyr701; #9171), anti-STAT3 (#9132), anti-phospho-STAT3 (Tyr705;
#9131), anti-C/EBPβ (LAP) (#3087), anti-C/EBPδ (#2318) and anti-C/EBPα (#8178)
from Cell Signaling Technologies; anti-PPARγ (sc-7196), anti-phospho ERK and antiERK (sc-93) from Santa Cruz Biotechnology; anti-aP2 (#10004944) from Cayman
Chemical Company; anti-mouse EpoR (#AF1390) and anti-Nurr1 (AF2156) from R&D
systems. Appropriate horseradish peroxidase-conjugated secondary antibodies (antirabbit, anti-mouse, anti-goat) were purchased from Vector laboratories, and detected by
enhanced chemiluminescence using ECL reagent (Thermo Scientific).

5. Quantitative Real-time PCR (qRT-PCR) analyses: Total RNA was isolated from
3T3-L1 cells at 48 h post-differentiation using an RNeasy kit (Qiagen). cDNA was
synthesized from 1 µg of mRNA using random primer and reverse transcriptase
(Promega). The expression of the relevant genes was determined by qRT-PCR using a
SYBR

Green-based

detection

system

(SA

Biosciences)

and

hypoxanthine

phosphoribosyltransferase (HPRT) gene as an internal control for normalization. The
primers used are shown in Table.1. All qRT-PCR measurements were performed using an
iCycler real-time PCR detection system (Bio-Rad) and the fold change in mRNA
expression was determined by the ∆∆CT method.
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6. Enzyme-linked immunosorbent assay (ELISA): Cell culture supernatants were
collected at the indicated time post-induction of adipocyte differentiation and assayed by
ELISA for the presence of IL-11 (Cat. No. DY418, R&D Systems) according to the
manufacturer’s instructions.

7. Immunoflourescence: 3T3-L1 preadipocytes were infected with YFP-CRTC2
encoding retroviruses as described earlier and induced to undergo adipogenesis using
standard MDI-induced differentiation protocol in the presence of MDI alone, PGF2α (25
nM) or PGF2α (25 nM) plus CsA (1 µg/ml). At the indicated time points, cells were fixed
with 3.7% formalin for 15 min at room temperature and then, washed 3 times with PBS.
The cells were permeabilized with 0.05% saponin in PBS and then, washed 3 times with
PBS. Then, the cells were incubated in dark with DAPI (0.5 µg/ml) in PBS for 10 min at
room temperature and then, washed 3 times with PBS. To keep the cells wet, 2 ml of PBS
was added to each well. The cells were examined and counted using fluorescence
microscopy (Olympus Inc, Center Valley, PA). At least 100 cells expressing YFPCRTC2 were counted per well and classified as cells with YFP-CRTC2 either completely
nuclear, completely cytoplasmic, more nuclear than cytoplasmic and more cytoplasmic
than nuclear. Then, the cells with YFP-CRTC2 completely nucleus and more nuclear than
cytoplasm were grouped as nuclear, whereas with completely cytoplasmic and more
cytoplasmic than nuclear were grouped as cytoplasmic.
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8. Luciferase assay: HEK293T cells were plated at the concentration of 5x104 cells per
well in 24 well plates. Next day, the cells were transfected with plasmids encoding either
GFP, Nurr1-WT (100 ng/well) or DN-Nurr1 (0, 100, 200 and 400 ng/well) as indicated
along with appropriate amount of GFP control plasmid to make the final concentration of
plasmids to 500 ng/well. Simultaneously, the cells were also transfected with the Nurr1
reporter, (NBRE)3-TK-LUC (Firefly; 50 ng/well) and pRG-TK (Renilla; 25 ng/well)
reporter plasmids. The transfection was performed using Attractene transfection reagent
(Qiagen, Cat. No. 301005) following manufacturer’s instructions. At 24 h posttransfection, Luciferase bioluminescence for each well was determined using Dualluciferase reporter assay system (Promega, Cat. No. E1910) following the manufacturer’s
instructions and TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA). Firefly
luciferase activity of each well was corrected using the corresponding Renilla luciferase
activity as a transfection efficiency control. The fold effect of (NBRE)3 activation by
DN-Nurr1 was determined with comparison to that of Nurr1-WT expression alone.

To determine the activation of ER-caCRTC2, HEK293T cells were plated as
described above and next day, the cells were transfected with either GFP or ERcaCRTC2 plasmids at the concentration of 400 ng/well along with the CREB reporter,
CRE-Luc (Firefly; 50 ng/well) and pRG-TK (Renilla; 25 ng/well) reporter plasmids as
described above. At 16 h post-transfection, cells were treated with either vehicle or
tamoxifen (500 nM). Cells were lysed at 4 h post-treatment and luciferase activity was
measured as described above.
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9. Statistical analysis: The data are expressed as the mean ± S.E.M. For comparison
between groups, either one-way ANOVA followed by Bonferroni post hoc test or
Student’s t test was employed. Differences were considered to be statistically significant
at p < 0.05.

TABLE 1. Nucleotide sequence of primers used for qRT-PCR
Gene
Il-11
Il-6
Hprt
Nurr1
Nur77
Nor1

Crtc1
Crtc2
Crtc3

Forward Primer
5’-CTGTGGGGACATGAA
CTGTG-3’
5’-AGTTGCCTTCTTGGGA
CTGA-3’
5’-GTTGGATACAGGCCA
GACTT TGTTG-3’
5’-CGGTTTCAGAAGTGCC
TAGC-3’
5’-ATGCCTCCCCTACCAA
TCTT-3’
5’-CCAAACCAAAGAGCCC
ACTA-3’
5’-CTGCCTTCCAAACCAA
AGAG-3’
5’- TCAGCCTTTTTGGAG
CTGTT-3’
5’-AGAACGGTGCAGAAAA
ATGC-3’
5’-CACCAGAGCACAATGA
CACC-3’
5’-TGGATGCTAAAGTCCC
TGCT-3’
5’-TTCCAGCCATCACTTC
ATCA-3’

Reverse Primer
5’-CGTCAGCTGGGAATT
TGTCT-3’
5’-TCTGCAAGTGCATCAT
CGTT-3’
5’-GAGGGTAGGCTGGCC
TATAGGCT-3’
5’-TTGCCTGGAACCTGGA
ATAG-3’
5’-TCTGCCCACTTTCGGAT
AAC-3’
5’-GGCCGTCAGAAGGTTG
TAGA-3’
5’-GGCCGTCAGAAGGTTG
TAGA-3’
5’-TAACCCATGTCGCTCT
GTGA-3’
5’-TAGTGGGCTCTTTGGT
TTGG-3’
5’-GCCTTCTTTGAGTCCC
ATGA-3’
5’-TAGCAGGCTGGTCAGG
AGAT-3’
5’-AGCTCTCATCCAGGTG
CTGT-3’

CHAPTER III
THE PGF2α/CALCINEURIN-SIGNALING PATHWAY INHIBITS
ADIPOGENESIS VIA AN AUTOCRINE/PARACRINE-MEDIATED
IL-11/GP130/STAT1-DEPENDENT SIGNALING CASCADE

1. Introduction: Adipocytes are specialized cells that form adipose tissue and are known
to regulate energy homeostasis and whole body metabolism (Rosen and Spiegelman,
2006). The excessive accumulation of adipose tissue due to hypertrophy and hyperplasia
of adipocytes contributes to the development of obesity which is associated with comorbidities such as insulin resistance, type 2 diabetes, cardiovascular diseases and some
cancers (De Pergola and Silvestris, 2013; Kahn and Flier, 2000; Kahn et al., 2006;
Nakamura et al., 2013; Nishimura et al., 2009; Van Gaal et al., 2006). Recent findings
support that the generation of new insulin-sensitive adipocytes through adipogenesis
plays a protective role in the development of type 2 diabetes in obesity (Tan and VidalPuig, 2008; Virtue and Vidal-Puig, 2010). However, obesity is considered as an
inflammatory condition (Gregor and Hotamisligil, 2011) and several inflammatory
mediators are known to inhibit adipogenesis (Gustafson and Smith, 2006; Xu et al.,
1999). Given the protective role of adipogenesis in the development of obesity associated
complications, it is important to understand the molecular mechanisms by which these
inflammatory mediators inhibit adipogenesis to identify better targets to treat obesity and
the associated complications. An inflammatory mediator that is known to inhibit
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adipogenesis both in vitro and in vivo is PGF2α (Casimir et al., 1996; Liu and Clipstone,
2007; Miller et al., 1996; Volat et al., 2012). In our attempts to understand the underlying
molecular mechanisms, our previous studies showed that PGF2α inhibits adipocyte
differentiation through activation of the calcium-dependent phosphatase, calcineurin (Liu
and Clipstone, 2007). In this chapter, we further extended our studies and demonstrate
that the PGF2α/calcineurin-signaling pathway inhibits adipogenesis through activation of
an autocrine/paracrine-mediated IL-11/gp130/STAT1- dependent signaling cascade.

2. Interleukin-11 (IL-11) cytokine: IL-11 is a multifunctional cytokine belonging to IL6 family of cytokines which also consists of IL-6, LIF (leukemia inhibitory factor), OSM
(oncostatin M), CNTF (ciliary neurotrophic factor), CT-1 (cardiotrophin-1) and CLC
(cardiotrophin-like cytokine) (Heinrich et al., 2003; Taga and Kishimoto, 1997). All
these family members bind to specific transmembrane, non-signaling α-subunit and
signal through recruitment of a common β-subunit called glycoprotein 130 (gp130)
(Heinrich et al., 2003; Taga and Kishimoto, 1997). Though gp130 is ubiquitously
expressed, expression of specific α-chain determines the tissue specificity of each IL-6
family members. IL-11 is a peliotrophic cytokine with multiple biological effects
including hematopoiesis, lymphopoiesis, immune response and cell differentiation
(Bozza et al., 2001; Du et al., 1993; Suga et al., 2001; Weich et al., 1997). In addition, IL11 is over expressed in certain tumors and has been shown to play a role in the
development and metastasis of certain tumors (Grivennikov, 2013; Onnis et al., 2013).
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2.1 IL-11 signaling: IL-11 signals through a hexameric receptor complex consisting of
two molecules each of ligand-binding IL-11 α-subunit (IL-11Rα) and the gp130 coreceptor β-chain signaling receptor (Barton et al., 2000). The IL-11Rα subunit lacks
intrinsic signaling capacity, however, binding of IL-11 to IL-11Rα promotes the
formation of a complex with gp130 and subsequent gp130 heterodimerization, thereby
allowing the activation of the gp130-associated JAK kinases and phosphorylation of
critical conserved tyrosine residues within the gp130 cytoplasmic domain that are
responsible for the recruitment and activation of specific downstream signaling molecules
(Heinrich et al., 2003; Taga and Kishimoto, 1997). Specifically, phosphorylation of Y759
within the gp130 cytoplasmic domain forms a docking site for the SHP2 adaptor protein
that is responsible for triggering the activation of the Ras-Raf-mitogen-activated protein
kinase (MAPK) signaling pathway, whereas phosphorylation of Y767, Y814, Y905 and
Y915 results in the recruitment of STAT1 and STAT3 to gp130. Once recruited to the
receptor complex, STAT1 and STAT3 are phosphorylated by JAKs and then, they homo
and/or hetrodimerize, translocate to the nucleus and regulate gene expression (Figure 3)
(Heinrich et al., 2003).

2.2 Role of IL-11 in inhibiting adipogenesis: IL-11 was initially cloned as an
adipogenesis inhibitory factor (AGIF) from human bone-marrow derived stromal cell line
as the supernatant collected from the COS-1 cells that overexpress AGIF cDNA inhibited
differentiation of 3T3-L1 cells into adipocytes and thus, provided initial evidence that
IL-11 is a potent inhibitor of adipocyte differentiation (Kawashima et al., 1991).
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FIGURE 3. Schematic model showing the IL-11/gp130-dependent signaling
pathways.
IL-11 binds to non-signaling α chain and recruits signaling subunit, gp130 co-receptor.
Then, the JAKs associated with gp130 phosphorylate specific tyrosine residues in the
cytoplasmic domain of gp130, resulting in the recruitment of STATs, which are then
phosphorylated by JAKs, homo/heterodimerize, translocate to nucleus and induce gene
expression.
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In human long-term marrow culture that has a potential to differentiate into myeloid cells
and adipocytes, IL-11 inhibited these cells to differentiate into adipocytes, whereas
promoted them to differentiate into hematopoietic cells (Keller et al., 1993). This further
provided evidence that IL-11 is a potent inhibitor of adipogenesis in hematopoietic
microenvironment. Further, IL-11 secreted by breast tumor cells inhibited the
differentiation of fibroblast into adipocytes (Meng et al., 2001). Thus, several studies
using cell culture system show that IL-11 inhibits adipogenesis. The physiological role of
IL-11 in regulating adipogenesis is evident from the analysis of the P6 strain of
senescence-accelerated

mice

(SAMP6).

These

mice

showed

a

decrease

in

osteoclastogenesis and osteoblastogenesis, whereas they showed increased adipose tissue
in bone marrow compared to control mice (Kajkenova et al., 1997). Further analysis of
the bone marrow stromal cells from these mice showed a decreased expression of IL-11
and an increased potential to differentiate into adipocytes (Kodama et al., 1998). Further,
transgenic mice with IL-11 overexpression showed a significantly increased bone mass
and cortical thickness, suggesting that IL-11 promotes osteoblastogenesis (Takeuchi et
al., 2002). These findings show that IL-11 physiologically inhibits adipocyte
differentiation, whereas promotes osteoblast differentiation. Collectively, therefore,
multiple evidence support that IL-11 is a potent inhibitor of adipocyte differentiation.
However, the precise molecular mechanisms and downstream signaling pathways
involved in mediating the inhibitory effects of IL-11 on adipogenesis are not known.
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3. STAT transcription factors: The STAT proteins are a family of latent cytoplasmic
transcription factors that consist of STAT1, STAT2, STAT3, STAT4, STA5a, STAT5b
and STAT6. These proteins are activated by interferons, IL-6 family of cytokines, growth
hormone, erythropoietin, leptin and others (Brierley and Fish, 2005). Binding of these
factors to their cognate receptors activate JAKs, which inturn phosphorylate specific
tyrosine residues in the cytoplasmic tail of the receptor to generate docking sites for
STAT proteins and subsequently, STATs are recruited to the receptor complex (Fu et al.,
1992; Platanias et al., 1994; Schindler et al., 1992). Once recruited to the receptor
complex, STAT proteins are phosphorylated by JAKs and then, they homo or
heterodimerize, transloacte to nucleus and induce gene expression (Darnell, 1997). The
genes induced by these STAT transcription factors are known to regulate various
biological and pathological process including cell growth and differentiation,
metabolism, hematopoiesis, host defense, immunoregulation and cancer development
(Bromberg and Darnell, 2000; O'Shea et al., 2013; Xu et al., 2013).

3.1 Expression of STATs during adipogenesis: Studies with 3T3-L1 cells and human
subcutaneous preadipocytes showed that several STAT proteins are expressed and
regulated during adipogenesis (Harp et al., 2001; Stephens et al., 1996). STAT1, STAT3
and STAT5 proteins are minimally expressed in undifferentiated 3T3-L1 cells, whereas
their expression significantly increases after adipogenic stimulation. While STAT3
expression remains at the same level, STAT1 and STAT5 expression decreases after 24 h
of induction and again increases after 96 h. Further, STAT6 is expressed at high level in
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preadipocytes and the level of expression remains constant during adipogenic process. In
contrast, STAT2 and STAT4 are not expressed in preadipocytes (Stephens et al., 1996).
Although several STAT family members are expressed during adipogenesis, STAT5 has
extensively been studied and has been shown to positively regulate adipogenesis (White
and Stephens, 2010). Recent evidences show that STAT3 positively regulates
adipogenesis (Wang et al., 2009; Zhang et al., 2011), whereas STAT1 inhibits
adipogenesis (McGillicuddy et al., 2009) which is discussed below.

3.2 Role of STAT3 in adipogenesis: While STAT3 level remains constant throughout
adipogenesis, it is highly phoshorylated and translocated into nucleus within 2 h of
adipogenic stimulation. This phosphorylation seems to be regulated by JAK2 as both the
inhibitor of JAK2/STAT3 activation, AG490 and depleting JAK2 expression using
siRNA decrease the STAT3 phosphorylation during adipogenesis (Wang et al., 2009).
Initial studies linked the early phosphorylation and activation of STAT3 to cell
proliferation and mitotic clonal expansion phase of adipogenesis (Deng et al., 2000).
Further, STAT3 has been shown to bind to DNA during this phase. Later studies showed
that STAT3 directly bind to C/EBPβ promoter during the early stages of adipogenesis
and regulates its expression (Zhang et al., 2011). This is a highly possible mechanism as
multiple evidence shows that C/EBPβ plays an important role in the regulation of critical
mitotic clonal expansion phase of adipogenesis (Tang et al., 2003a). Further evidence for
the role of STAT3 in adipogenesis is evident from the findings that the expression of a
dominant-negative STAT3 and knockdown of STAT3 expression using siRNA blocks
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adipogenesis (Wang et al., 2009). Collectively, STAT3 plays a positive role in
adipogenesis by regulating C/EBPβ expression and mitotic clonal expansion.

3.3 Role of STAT1 in adipogenesis: The activation of STAT1 appears to inhibit
adipocyte differentiation as the stimulation of adipogenesis in the presence of INFγ, a
potent activator of STAT1, inhibits adipogenesis (McGillicuddy et al., 2009). In mature
adipocytes, INFγ treatment resulted in strong activation and nuclear translocation of
STAT1 which correlated with a substantial decrease in PPARγ expression (Waite et al.,
2001). Further studies identified a potential consensus sequence of interferon-γ-activated
site (GAS) elements in the PPARγ2 promoter and indeed, STAT1 homodimers are shown
to bind an IFNγ-responsive site within the PPARγ2 promoter in 3T3-L1 cells (Hogan and
Stephens, 2001). Collectively, the available evidence suggests that activation of the
STAT1 transcription factor inhibits adipogenesis through possibly inhibiting the
expression of PPARγ.

4. Role of ERK in adipogenesis: ERK has been shown to both positively and negatively
regulate adipocyte differentiation. While ERK has been shown to positively regulate
adipogenesis by phosphorylating C/EBPβ during the early stage of adipogenesis (Tang et
al., 2005), angiotensin-mediated activation of ERK has been shown to inhibit adipocyte
differentiation (Fuentes et al., 2010). Further, mechanical stretch induced activation of
ERK has been shown to inhibit adipogenesis through down regulation of PPARγ
expression (Tanabe et al., 2004). Thus activation of ERK during early stage of
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differentiation promotes adipogenesis, whereas its activation in the later stage inhibits
adipogenesis by blocking PPARγ expression.
In this chapter, we investigated the role IL-11 in mediating the inhibitory effects
of PGF2α on adipogenesis. First, we show that PGF2α induces IL-11 expression during
adipogenesis in a calcineurin-dependent mechanism. Next, using IL-11 specific shRNA
and a dominant-negative gp130, we demonstrate that IL-11/gp130-mediated signaling is
required for the inhibitory effects of PGF2α on adipogenesis. Further, using a panel of
chimeric, mutant gp130 receptors, we identify that the gp130-mediated activation of
STAT1 transcription factor inhibits adipogenesis. In addition, using STAT1 specific
shRNAs, we demonstrate that STAT1 is required for the inhibitory effects of IL-11 and
PGF2α on adipogenesis. Collectively, our results provide evidence that the
PGF2α/calcineurin-signaling

pathway

inhibits

adipocyte

differentiation

through

activation of an autocrine/paracrine IL-11/gp130/STAT1-dependent signaling.

5. RESULTS
5.1 Activation of the PGF2α/calcineurin-signaling pathway induces the expression
of IL-11 in differentiating 3T3-L1 preadipocytes. In previous studies we had
demonstrated that PGF2α inhibits the early stages of adipocyte differentiation via the
essential actions of the calcineurin phosphatase (Liu and Clipstone, 2007). Since
calcineurin is a well-known positive regulator of a number of transcription factor
(Crabtree, 2001), we hypothesized that the PGF2α/calcineurin-signaling pathway was
likely to inhibit adipogenesis via the increased expression of a gene(s) capable of

53

FIGURE 4. PGF2α treatment of differentiating 3T3-L1 preadipocytes induces the
calcineurin-dependent expression and secretion of IL-11.

Two-day post-confluent 3T3-L1 preadipocytes were induced to undergo adipocyte
differentiation by treatment with MDI in the presence of either vehicle, PGF2α (25 nM)
alone or PGF2α (25 nM) plus Cyclosporin A (CsA) (1 µg/ml). At 48 h post-stimulation,
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total RNA and cell culture supernatants were collected and the expression of IL-11 was
determined by qRT-PCR (A) and ELISA (B), respectively. The expression of IL-6 was
determined by qRT-PCR (C). The data is shown as mean ± SEM (either one-way
ANOVA followed Bonferroni post hoc test or Student’s t test; p<0.05; n=3). ND; not
detectable. Results are representative of at least three independent experiments.
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inhibiting the differentiation process. In order to test this hypothesis, we initially
performed a microarray gene expression profiling experiment to identify candidate antiadipogenic genes induced by PGF2α in a calcineurin-dependent fashion during the early
stages of 3T3-L1 preadipocyte differentiation. Amongst the most highly induced genes
identified by this analysis was the multifunctional cytokine IL-11. This observation was
of significant interest, as IL-11 had previously been shown to be a potent inhibitor of
adipocyte differentiation (Kawashima et al., 1991; Keller et al., 1993).
To confirm our initial microarray result, we performed quantitative RT-PCR and
ELISA experiments to analyze the expression of IL-11 in 3T3-L1 cells induced to
undergo adipocyte differentiation in the presence or absence of PGF2α. As shown in
Figure 4, while 3T3-L1 preadipocytes induced to undergo adipocyte differentiation by the
standard MDI-induced protocol expressed essentially undetectable levels of IL-11
at 48 h-post stimulation, significant levels of both IL-11 mRNA (Fig. 4A) and protein
(Fig. 4B) were readily observed in cells induced to differentiate in the presence of
PGF2α, an effect that was attenuated in the presence of the calcineurin-specific inhibitor
cyclosporin A (CsA). In fact, we observed that treatment of non-differentiated 3T3-L1
cells with PGF2α alone was sufficient to induce IL-11 expression, although in this case
the level of induction (~3-fold; data not shown) was significantly less than that observed
in the presence of the MDI adipogenic cocktail (23-fold; see Fig. 4A). As IL-11 is a
member of the IL-6 family of cytokines (Taga and Kishimoto, 1997), we also
investigated whether PGF2α affected the expression of other family members during the
differentiation process. In this respect, while our initial microarray data and subsequent
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qRT-PCR analysis revealed that the expression of IL-6 itself was induced by PGF2α
treatment, the level of induction observed (3.5-fold) was considerably lower compared to
the effect on IL-11 (Fig. 4C), whereas no substantial effect of PGF2α on the expression
of other members of this family was observed. Taken together, therefore, our results
indicate that the activation of the PGF2α/calcineurin-signaling pathway synergizes with
MDI-induced signals during the early stages of 3T3-L1 preadipocyte differentiation to
specifically induce the robust expression and subsequent secretion of the IL-11 cytokine,
which given the known anti-adipogenic effects of IL-11 (Kawashima et al., 1991; Keller
et al., 1993), raised the possibility that PGF2α might act to inhibit adipogenesis by means
of an IL-11 mediated autocrine mechanism.

5.2 IL-11 and gp130 cytokine co-receptor-dependent signaling play a role in
mediating the inhibitory effects of PGF2α on adipocyte differentiation. Since IL-11
signaling is known to be critically dependent upon the actions of the gp130 cytokine coreceptor signaling subunit (Barton et al., 2000), we initially took advantage of a wellcharacterized dominant-negative form of gp130 (DN-gp130) (Kumanogoh et al., 1997) to
examine the potential role of IL-11 in mediating the inhibitory effects of the
PGF2α/calcineurin-signaling pathway on adipocyte differentiation. This dominantnegative gp130 mutant comprises the extracellular domain of gp130 known to be
responsible for interacting with IL-11/IL-11Rα complexes, but lacks the cytoplasmic
domain containing the conserved residues required for signal transduction. Consequently,
ectopic expression of DN-gp130 should act to attenuate gp130-dependent signaling
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FIGURE 5. gp130-dependent signaling play a role in mediating the inhibitory effects
of PGF2α on adipocyte differentiation.

3T3-L1 preadipocytes transduced with either MSCV-GFP or MSCV-DN-gp130
retroviruses were induced to undergo differentiation with MDI in the presence of the
indicated concentrations of PGF2α for the initial 48 h and the extent of adipocyte
differentiation was determined at day 8 by either ORO staining (A) or immunoblotting

58
for the expression of PPARγ and aP2 (B). Equal protein loading was confirmed by
probing with a control antibody directed against ERK. Results are representative of at
least three independent experiments.
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events by sequestering IL-11 in non-functional complexes incapable of signaling. Thus,
to initially establish the potential role of gp130 signaling in mediating the inhibitory
effects of PGF2α on adipocyte differentiation, 3T3-L1 preadipocytes were transduced
with either a control retrovirus or a retrovirus encoding DN-gp130, and then induced to
undergo differentiation by the standard MDI-induced adipogenic protocol in the presence
of various concentrations of PGF2α. As expected, the graded doses of PGF2α served to
produce a potent dose-dependent inhibition of adipocyte differentiation in control cells,
as measured by a decrease in cells staining positive for Oil Red O (ORO) (Fig. 5A) and
the decreased expression of the adipocyte-specific genes PPARγ and aP2 (Fig. 5B). In
contrast, we found that ectopic expression of DN-gp130 was able to greatly attenuate the
inhibitory activity of PGF2α, allowing 3T3-L1 preadipocyte cells to differentiate in the
presence of concentrations of PGF2α that were able to potently inhibit the differentiation
of control cells (Figs 5A, B). This result demonstrates that inhibiting gp130-dependent
signaling in 3T3-L1 preadipocytes is able to partially rescue adipocyte differentiation in
cultures containing PGF2α, thereby suggesting a critical role for gp130 signaling in
mediating the inhibitory effects of PGF2α on adipocyte differentiation.
While the gp130 cytokine co-receptor signaling subunit is an essential component
of the IL-11 receptor (Barton et al., 2000), it is also known to be involved in mediating
the signaling of other members of the IL-6 family of cytokines (Heinrich et al., 2003;
Taga and Kishimoto, 1997). Consequently, to more directly assess the role of IL-11 in

60

FIGURE 6. IL-11 play a role in mediating the inhibitory effects of PGF2α on
adipocyte differentiation.

(A, B) 3T3-L1 preadipocytes transduced with retroviruses encoding either control or IL11-specific shRNA were induced to undergo differentiation with MDI in the absence or
presence of PGF2α (12.5 nM) for the initial 48 h. After 8 days, the extent of adipocyte
differentiation was assessed by ORO staining (A) or immunoblotting for the expression
of PPARγ and aP2 (B). Equal protein loading was confirmed by probing with a control
antibody directed against ERK. (C) The efficiency of knockdown of IL-11 mRNA was
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determined by qRT-PCR using RNA isolated from PGF2α-treated cells at the 48 h time
point. The data is shown as mean ± SEM (One-way ANOVA followed by Bonferroni
post hoc test; p<0.05; n=3). Results are representative of at least three independent
experiments.
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mediating the inhibitory effects of PGF2α on adipocyte differentiation, we adopted a
shRNA-mediated knockdown strategy in which 3T3-L1 preadipocytes were transduced
with retroviruses encoding either a control shRNA or an shRNA-specific for IL-11, then
subsequently examined for their ability to undergo adipocyte differentiation in the
presence of an inhibitory concentration of PGF2α (12.5 nM). As expected, the ability of
control shRNA-transduced 3T3-L1 preadipocytes to undergo adipocyte differentiation
under these conditions was potently inhibited, as determined by both loss of OROstaining cells and decreased expression of PPARγ and aP2 (Fig. 6A, B). Conversely, in
IL-11 specific shRNA-transduced cultures induced to undergo differentiation in the
presence of this same inhibitory concentration of PGF2α, we consistently observed the
rescue of adipocyte differentiation, as indicated by the presence of significant patches of
ORO-staining cells and the expression of both PPARγ and aP2 (Fig. 6A, B). In these
experiments we found that the IL-11 specific shRNA was typically able to reduce the
level of IL-11 induced in PGF2α-treated 3T3-L1 preadipocytes by approximately 70%
compared to control shRNA-expressing cells (see Fig. 6C). These results therefore
provide evidence that IL-11 likely plays an important role in mediating the inhibitory
effects of the PGF2α/calcineurin-signaling pathway on adipocyte differentiation and are
consistent with a model in which PGF2α-induces the initial expression and subsequent
secretion of IL-11, which then acts in an autocrine/paracrine fashion to inhibit adipocyte
differentiation by means of a gp130 cytokine co-receptor-dependent pathway.
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FIGURE 7. Schematic model illustrating the chimeric EpoR/gp30 receptors used in
this study.

The array of chimeric EpoR/gp130 receptors used in this study comprising of the
extracellular ligand-binding domain of the EpoR (grey ovals) fused to various amino
acid-substituted versions of the intracellular domain of gp130 (open rectangles) are
shown. The position of the conserved tyrosine residues in the gp130 cytoplasmic domain
and corresponding tyrosine to phenylalanine substitutions are indicated, as are the
synthetic peptide sequences used for the selective activation of STAT1 and STAT3 in the
EG-4F-STAT1 and EG-4F-STAT3 “add-back” mutants.
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FIGURE 8. gp130-dependent
differentiation.

signaling

is

sufficient

to

inhibit

adipocyte

3T3-L1 preadipocyte cells were initially infected with either MSCV-GFP or MSCV-EGWT retroviruses then super-infected with either MSCV-DsRed or MSCV-DsRed-PPARγ
retroviruses, as indicated. (A) The expression of EG-WT and PPARγ was confirmed by
immunoblotting with antibodies specific for EpoR and PPARα, while equal protein
loading was confirmed by immunoblotting with a control antibody directed against ERK.
(B, C) Two-day post-confluent cells were then induced to differentiate with MDI in the
presence or absence of Epo for the initial 48 h and the degree of adipocyte differentiation
was assessed at day 8 post-stimulation by ORO staining (B) and immunoblotting for the
expression of PPARγ and aP2 (C). Equal protein loading was confirmed by probing with
a control antibody directed against ERK. Results are representative of more than three
independent experiments.
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5.3 gp130 cytokine co-receptor-dependent signaling is sufficient to inhibit adipocyte
differentiation by blocking the expression of PPARγ. Next, we determined whether
gp130 signaling per se was sufficient to inhibit adipocyte differentiation. For this
experiment, we took advantage of a previously characterized chimeric form of gp130 in
which the cytoplasmic signaling domain of gp130 is fused to the extracellular ligandbinding domain of the erythropoietin receptor (EpoR/gp130; EG-WT; see Fig. 7), which
allows gp130-specific signaling events to be induced in response to stimulation with
erythropoietin (Epo) (Schaper et al., 1998; Schmitz et al., 2000). As shown in Fig. 8, the
presence of Epo in the culture medium had no effect on the ability of control GFPexpressing cells to undergo adipocyte differentiation, but conversely was able to potently
inhibit the differentiation of cells ectopically expressing the EG-WT chimeric receptor, as
measured by a decrease in both ORO staining and the expression of PPARγ and aP2 (Fig.
8B, C). Furthermore, we found that ectopic expression of PPARγ in cells expressing the
EG-WT chimeric receptor was able to bypass the inhibitory effects of Epo on adipocyte
differentiation in these cells (Fig. 8B, C). Taken together, these data indicate that gp130
signaling per se is sufficient to inhibit adipocyte differentiation, most likely by acting to
block the expression of the pro-adipogenic master regulatory transcription factor, PPARγ.

5.4 C-terminal tyrosine residues involved in the activation of STAT transcription
factors play a critical role in mediating the inhibitory effects of gp130 signaling on
adipocyte differentiation. Signaling via gp130 is critically dependent upon conserved
tyrosine residues located within the cytoplasmic domain, which are phosphorylated in
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FIGURE 9. Tyrosine residues involved in STAT transcription factor activation play
a role in mediating the inhibitory effects of gp130-dependent signaling on adipocyte
differentiation.

(A) 3T3-L1 preadipocyte cells were infected with either MSCV-GFP, EG-WT, EG-1F, or
EG-4F encoding retroviruses and the expression of each chimeric receptor was
determined by immunoblotting with an antibody specific for EpoR, while equal protein
loading was confirmed by immunoblotting with a control antibody directed against ERK.
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(B) To confirm the ability of the chimeric receptors to activate STAT1 and STAT3,
whole cell extracts from cells induced to differentiate with MDI in the presence of Epo
were analyzed by immunoblotting at the indicated times with antibodies specific for
pSTAT1-Y701, STAT1, pSTAT3-Y705, and STAT3. (C) To determine the activation of
ERK by the chimeric receptors, whole cell extracts from 90% confluent cells treated with
Epo in serum free medium were collected at the indicated time and analyzed by
immunoblotting with antibodies specific for pERK and ERK. (D, E) Two-day postconfluent cells were induced to differentiate with MDI in the presence of Epo for the
initial 48 h. After 8 days, adipocyte differentiation was assessed by ORO staining (C) and
immunoblotting for the expression of PPARγ and aP2 (D). Results are representative of
more than three independent experiments.
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response to receptor activation and are responsible for recruiting cytoplasmic signaling
molecules involved in the propagation of specific downstream signaling pathways
(Heinrich et al., 2003; Taga and Kishimoto, 1997). IL-11 signaling mediated via the
gp130 co-receptor signaling subunit is known to primarily activate two independent
downstream effectors pathways: the ERK and JAK/STAT signaling pathways (Heinrich
et al., 2003; Taga and Kishimoto, 1997). In order to ascertain which of these gp130dependent signaling events were responsible for mediating the inhibition of adipocyte
differentiation, we took advantage of previously well-characterized EpoR/gp130 chimeric
mutants known to be selectively deficient in the activation of one or another of these
signaling pathways (Schaper et al., 1998; Schmitz et al., 2000). Specifically, we utilized
chimeric mutant receptors with either a Y759F substitution (EG-1F) that is known to be
selectively deficient in the activation of the downstream ERK pathway, or a quadruple
chimeric mutant receptor containing Y767F, Y814F, Y905F and Y915F substitutions
(EG-4F) that is selectively deficient in the activation of the STAT1 and STAT3 latent
transcription factors (see Fig. 7 for details). Each of these mutant receptors, along with
EG-WT, was independently introduced into 3T3-L1 preadipocytes by retroviral
transduction, and immunoblot analysis was performed to confirm that each receptor was
expressed at comparable levels (Fig. 9A). Subsequently, cells were then induced to
undergo adipocyte differentiation by the standard MDI-induced protocol in either the
presence or absence of Epo, and the effects on differentiation were assessed. As shown in
Figure 9D and E, the presence of Epo was able to inhibit the differentiation of EG-1Fexpressing cells to essentially the same degree as that observed for cells expressing EG-
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WT. By contrast, the presence of Epo had no effect on the ability of EG-4F expressing
cells to differentiate. As shown in Figure 9B, immunoblot analysis confirmed that unlike
EG-WT and EG-1F, the EG-4F receptor was deficient in its ability to efficiently activate
STAT1 and STAT3 in response to Epo stimulation. Further, as shown in Figure 9C,
unlike EG-4F, the EG-1F receptor was deficient in its ability to activate ERK. These data
therefore demonstrate that the four C-terminal tyrosine residues present in the
cytoplasmic domain of gp130 are required for the gp130-mediated inhibition of adipocyte
differentiation. Moreover, since these latter tyrosine residues are required for the gp130mediated activation of STAT1 and STAT3, the data further suggests a potentially
important role for the activation of STAT transcription factors in mediating the inhibitory
effects of gp130 co-receptor signaling on adipocyte differentiation.

5.5 A critical role for STAT1 in mediating the inhibitory effects of gp130, IL-11 and
PGF2α on adipocyte differentiation. To further examine the potential role of STAT1
and STAT3, we next generated chimeric gp130 “add-back” receptors in which consensus
peptide sequences previously reported to selectively activate either STAT1 or STAT3
(Gerhartz et al., 1996) were fused in-frame to the C-terminus of STAT signaling-deficient
EG-4F mutant receptor, thereby generating EG-4F-STAT1 and EG-4F-STAT3,
respectively (see Fig. 7). Each of these mutant “add-back” receptors, along with the
parental EG-4F receptor, was independently expressed in 3T3-L1 preadipocytes (Fig.
10A) and their ability to activate STATs (Fig. 10B) and inhibit adipocyte differentiation
(Fig. 10C, D) was assessed. As shown in Figure 10B, Epo-treatment of cells expressing
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FIGURE 10. gp130-dependent selective activation of STAT1, but not STAT3 inhibits
adipocyte differentiation.

(A) 3T3-L1 preadipocyte cells were infected with either EG-4F, EG-4F-STAT1 or EG4F-STAT3 encoding retroviruses and their expression was assessed by immunblotting the
whole cell extracts with an antibody specific for EpoR, and ERK as a control for equal
protein loading. (B) To determine the activation selectivity of the chimeric add-back
receptors, the above cells were induced to differentiate with MDI in the presence of Epo
and whole cell extracts prepared at the indicated times were analyzed by immunoblotting
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with antibodies specific for pSTAT1-Y701, STAT1, pSTAT3-Y705 and STAT3. (C, D)
Two-day post-confluent cells from (A) were induced to differentiate with MDI in the
presence of Epo and after 8 days, the extent of adipocyte differentiation was assessed by
ORO staining (C) and immunoblotting for the expression of PPARγ and aP2 (D). Results
are representative of more than three independent experiments.
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the EG-4F-STAT1 mutant receptor resulted in the preferential activation of STAT1,
whereas Epo-stimulation of EG-4F-STAT3-expressing cells led to the preferential
activation of STAT3. We note that although the EG-4F receptor is completely deficient in
its ability to activate STAT1, it is still able to induce residual levels of STAT3 activation,
albeit considerably reduced compared to EG-WT (see Fig 10B). Based upon analysis of
mutant receptors lacking all cytoplasmic tyrosine residues, we believe that this effect is
likely due to the ability of gp130-associated JAK2 to very inefficiently activate parallel
gp130-independent pathways leading to STAT3 activation (data not shown).
Nonetheless, it is clear from our data that EG-4F-STAT1 and EG-4F-STAT3
preferentially activate STAT1 and STAT3, respectively. When 3T3-L1 preadipocytes
expressing these mutant receptors are induced to differentiate in the presence of Epo, we
find that only those cells expressing EG-4F-STAT1 are blocked from undergoing
adipogenesis, as measured by a decrease in both ORO staining (Fig. 10C) and the
expression of PPARγ and aP2 (Fig. 10D). These data therefore suggest that it is the
activation of the STAT1 transcription factor, rather than STAT3, that is associated with
the ability of gp130 to inhibit adipocyte differentiation.
In order to further define the role of STAT1 as a critical anti-adipogenic effector
of the gp130-signaling pathway, we next chose to determine whether STAT1 function
was necessary for the ability of gp130-induced signaling to inhibit adipocyte
differentiation. To accomplish this goal, we adopted a shRNA knockdown strategy using
STAT1-specific shRNAs to stably deplete endogenous STAT1 levels in 3T3-L1
preadipocytes. By initially screening a panel of STAT1-specific shRNAs we were able to
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FIGURE 11. STAT1-depletion rescues adipocyte differentiation from the
EpoR/gp130-chimeric receptor signaling.

(A) 3T3-L1 preadipocyte cells transduced with retroviruses encoding either a control
shRNA or one of two independent STAT1-specific shRNAs (924 & 927), were superinfected with a MSCV-EG-WT encoding retrovirus and whole cell extracts from these
cells were analyzed by immunoblotting with antibodies specific for STAT1, EpoR and
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STAT3 as a protein loading control and to show specificity of the shRNA knockdown.
(B, C) These independent cell populations were then induced to differentiate with MDI in
the presence of Epo for the initial 48 h and after 8 days, the extent of adipocyte
differentiation was assessed by ORO staining (B) and immunoblotting for the expression
of PPARγ and aP2 (C). Results are representative of two independent experiments.
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FIGURE 12. STAT1-depletion rescues adipocyte differentiation from the IL-11
cytokine.

3T3-L1 preadipocyte cells transduced with either control shRNA or STAT1-specific
shRNA (924 & 927) encoding retroviruses were induced to differentiate with MDI in the
presence of IL-11 for the initial 48 h and the extent of adipocyte differentiation was
assessed at day 8 by either ORO staining (A) or immunoblotting for the expression of
PPARγ and aP2 (B). Results are representative of two independent experiments.
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identify two independent shRNAs capable of efficiently and specifically depleting
endogenous levels of STAT1 (Fig. 11A). 3T3-L1 preadipocytes expressing either of these
two independent STAT1-specific shRNAs or a control shRNA were then each
superinfected with a retrovirus encoding EG-WT and induced to undergo adipocyte
differentiation in the presence of Epo. As expected, when control shRNA expressing cells
were treated with Epo their differentiation was potently inhibited (Fig. 11B, C). In
contrast, we found that the inhibitory effect of Epo was greatly attenuated in cells
expressing either of the two STAT1-specific shRNAs (Fig. 11B, C). Similarly, we found
that these two STAT1-specific shRNAs also greatly attenuated the ability of exogenous
IL-11 to inhibit adipocyte differentiation (Fig. 12 A, B). It is noteworthy that in each case
the degree of rescue caused by each of the STAT1-specific shRNAs was proportional to
their degree of knockdown of endogenous STAT1 levels.
Next, we wished to examine the requirement for STAT1 as a downstream antiadipogenic effector of the PGF2α/calcineurin-signaling pathway. As shown in Fig. 13A,
B, while PGF2α effectively inhibited the differentiation of control shRNA-expressing
cells as expected, we found that depletion of endogenous STAT1 levels with either of our
STAT1-specific shRNAs allowed for significant rescue of adipogenesis in the presence
of inhibitory concentrations of PGF2α capable of potently inhibiting control cells. Taken
together, these data identify an important role for STAT1 as a critical downstream
effector in mediating the inhibitory effects of PGF2α and IL-11/gp130-signaling on
adipocyte differentiation.
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FIGURE 13. STAT1-depletion rescues adipocyte differentiation from PGF2α.
3T3-L1 preadipocyte cells transduced with either control shRNA or STAT1-specific
shRNA (924 & 927) encoding retroviruses were induced to differentiate with MDI in the
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presence of increasing concentrations of PGF2α for the initial 48 h and the extent of
adipocyte differentiation was assessed after 8 days by ORO staining (A) and
immunoblotting for the expression of PPARγ and aP2 (B). Results are representative of at
least five independent experiments.
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5.6 STAT1 depletion enhances the efficiency of adipocyte differentiation: Evidence
for an intrinsic negative regulatory role: In addition to the well-known anti-adipogenic
effects of exogenous PGF2α, prior studies have revealed that PGF2α also serves as an
important endogenous negative regulator of adipogenesis that is naturally synthesized
transiently by preadipocytes early during the normal differentiation process, and acts in
an autocrine-mediated, negative feedback loop to restrict the overall adipogenic capacity
of these cells (Fujimori et al., 2010a; Fujimori et al., 2010b; Silvestri et al., 2013). This
led us to hypothesize that this endogenous PGF2α-mediated negative feedback pathway
is also likely to involve the calcineurin/IL-11/gp130/STAT1 signaling axis that we have
described above. Consistent with this notion we find that 3T3-L1 preadipocyte cells
induced to differentiate by the standard MDI-induced adipogenic protocol transiently
secrete low levels of IL-11 early during the differentiation process, peaking at 24 hrs
post-induction and falling to background levels by 48 hrs (Fig. 14A). Moreover, we find
that this increase in IL-11 secretion is inhibited in the presence of CsA, indicating that it
is dependent upon the activation of calcineurin, which is presumably induced in response
to endogenously produced PGF2α. It is noteworthy, however, that the level of IL-11
secretion detected here during normal adipocyte differentiation is considerably less than
that induced in response to exogenous PGF2α (0.278 pg/ml versus 11.6 ng/ml).
Having demonstrated that IL-11 is naturally produced during the normal process
of adipocyte differentiation, we next sought to determine whether the IL11/gp130/STAT1 signaling axis served as an intrinsic negative regulator of the adipocyte
differentiation pathway designed to restrict the adipogenic potential of preadipocyte cells.
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FIGURE 14. STAT1-depletion enhances the efficiency of adipocyte differentiation in
response to suboptimal adipogenic stimulation.
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(A) 3T3-L1 cells were induced to differentiate by the standard MDI-induced protocol in
the presence and absence of CsA and culture supernatants were assayed after 24 h for the
presence of IL-11 by ELISA, (B, C) 3T3-L1 preadipocyte cells transduced with either
control shRNA or STAT1-specific shRNA (924) encoding retroviruses were exposed to a
suboptimal adipogenic cocktail comprising of decreasing serial dilutions of MD alone in
the absence of exogenously added insulin. After 8 days, the extent of adipocyte
differentiation was assessed by ORO staining (B) and immunoblotting for the expression
of PPARγ and aP2 (C). The extent of STAT1 depletion was confirmed by
immunoblotting for STAT1, while immunoblot analysis of STAT3 served as a control for
knockdown specificity and equal protein loading. The data is shown as mean ± SEM
(Student’s t test; p<0.05; n=3). ND; not detectable. Results are representative of three
independent experiments.
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We reasoned that if this were the case, then inhibition of this pathway should enhance the
efficiency of the differentiation process. For these experiments we took advantage of the
observation that treatment of 3T3-L1 preadipocytes with suboptimal adipogenic stimuli
(reduced concentrations of Mix and Dex in the absence of insulin) results in barely
detectable levels of adipocyte differentiation (Fig. 14B, C). However, in contrast, we find
that when the integrity of the IL-11/gp130/STAT1 signaling pathway is abrogated by
depletion of endogenous STAT1 proteins, a significant degree of adipocyte
differentiation is observed in response to these suboptimal doses of adipogenic stimuli
(Fig 14B, C). In fact, we find that even in the presence of optimal doses of adipogenic
stimuli, we consistently observe enhanced levels of adipocyte differentiation (as indicated
by increased ORO staining and expression of the adipogenic marker proteins, PPARγ and
aP2), in cells in which the IL-11/gp130/STAT1 signaling axis has been inhibited, either
as a result of STAT1 knockdown or via ectopic expression of DN-gp130 (see Fig. 5 and
13). Hence, these results strongly suggest that the IL-11/gp130/STAT1 signaling pathway
does indeed represent an intrinsic negative regulatory pathway that serves to restrict the
adipogenic potential of preadipocyte cells.

6. DISCUSSION
Recent studies identifying an emerging in vivo role for PGF2α as an important
endogenous negative regulator of adipocyte differentiation involved in opposing the
development of obesity and its contingent pathological metabolic sequelae (Volat et al.,
2012), have raised considerable interest in elucidating the molecular pathways and
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mechanisms by which this important prostaglandin mediates its inhibitory effects on
adipogenesis. Building upon our previous identification of calcineurin as a critical
downstream anti-adipogeneic effector of PGF2α (Liu and Clipstone, 2007), we have now
further delineated the molecular mechanism by which this signaling pathway inhibits
adipocyte differentiation. Collectively, our findings support a model in which exposure of
differentiating 3T3-L1 preadipocytes to PGF2α results in the initial calcineurindependent expression and secretion of the IL-11 cytokine, which then acts in an
autocrine/paracrine fashion to inhibit adipocyte differentiation via the essential actions of
the gp130 cytokine co-receptor signaling subunit and the subsequent activation of the
STAT1 transcription factor.
Our results clearly identify IL-11 as a downstream transcriptional target of the
PGF2α/calcineurin-signaling pathway in 3T3-L1 preadipocytes. Interestingly, this same
pathway has also recently been shown to induce IL-11 expression in endometrial
adenocarcinoma cells via the calcineurin-dependent activation of the nuclear factor of
activated T cells (NFAT) transcription factor family (Sales et al., 2010). By analogy with
this finding, together with the knowledge that NFAT proteins are expressed in 3T3-L1
preadipocytes (Ho et al., 1998), it is tempting to speculate that NFAT proteins are also
likely to play a role in coupling the PGF2α/calcineurin-signaling pathway to the
expression of IL-11 in these cells. However, the recent demonstration that IL-11 can be
transcriptionally regulated by the hypoxia-inducible factor 1 transcription factor (Onnis
et al., 2013), which we have previously shown is activated in 3T3-L1 cells in response to
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PGF2α stimulation (Liu and Clipstone, 2008), raises the possibility that this pathway
may also play a role.
IL-11 has long been known to be a potent inhibitor of adipocyte differentiation
(Kawashima et al., 1991; Keller et al., 1993). Moreover, 3T3-L1 preadipocytes are
known to express functional IL-11 receptors (Tenney et al., 2005). Hence, our
observation that activation of the PGF2α/calcineurin-signaling pathway in 3T3-L1
preadipocytes induces the expression and subsequent secretion of IL-11, strongly
suggested a model in which PGF2α inhibits adipocyte differentiation by means of an
autocrine IL-11-mediated negative regulatory pathway. Evidence in support of this model
is provided by our dual observation that both the shRNA-mediated knockdown of IL-11
and the dominant-negative inhibition of the gp130 cytokine co-receptor signaling subunit,
an essential signaling component of the IL-11 receptor, are both able to rescue 3T3-L1
preadipocyte differentiation in the presence of inhibitory concentrations of PGF2α.
Together, these results demonstrate that the ability of PGF2α to inhibit adipocyte
differentiation is dependent upon both IL-11 and gp130 cytokine co-receptor signaling. In
this regard, although the DN-gp130 mutant used in our experiments is capable of
inhibiting IL-11 signaling, it can also inhibit signaling via all other members of the IL-6
cytokine family, whose receptors all share the same gp130 cytokine co-receptor signaling
subunit (Heinrich et al., 2003; Taga and Kishimoto, 1997). However, of this family of
cytokines, we find that only IL-11 and, to a somewhat lesser extent, IL-6 (Fig.4), is
significantly induced by the PGF2α/calcineurin-signaling pathway in differentiating 3T3L1 preadipocytes. Hence, based upon our collective data, we conclude that IL-11, acting
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in an autocrine fashion via a critical gp130 cytokine co-receptor-dependent mechanism,
most likely plays the prominent role in mediating the inhibitory effects of the
PGF2α/calcineurin-signaling pathway on adipocyte differentiation, although we do not
rule out the possibility that IL-6, and potentially other related family members, may also
additionally contribute.
Having identified a clear role for the gp130-signaling axis in mediating the
inhibitory

effects

of

the

PGF2α/calcineurin-signaling

pathway

on

adipocyte

differentiation, and having further showed that the activation of gp130-dependent
signaling per se is sufficient to inhibit the adipogenic process, our attention naturally
focused towards investigating the underlying gp130-dependent mechanisms involved. In
this respect, signaling via the gp130 cytokine co-receptor signaling subunit has been
extensively characterized and is known to primarily involve the activation of both the
STAT1 and STAT3 latent transcription factors and the MAPK signaling pathway
(Heinrich et al., 2003). By turning to previously characterized chimeric mutants of gp130
known to be selectively deficient in the activation of either one of these latter pathways
(Schaper et al., 1998; Schmitz et al., 2000), we were able to interrogate their respective
roles in mediating the inhibitory effects of gp130 signaling on adipogenesis. Surprisingly,
although the MAPK signaling pathway has previously been shown to inhibit adipocyte
differentiation in certain contexts (Font de Mora et al., 1997; Tanabe et al., 2004), we
found that tyrosine 759, responsible for coupling gp130 to the activation of MAPK, was
completely dispensable for the inhibitory effects of gp130 signaling. Conversely, we
found that the ability of gp130 to inhibit adipocyte differentiation was critically
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dependent upon the conserved tyrosine residues known to be involved in the activation of
STAT1 and STAT3, suggesting a potentially important role for STAT transcription
factors. By adopting the use of additional gp130 mutant receptors that are preferentially
able to activate either STAT1 or STAT3 (Gerhartz et al., 1996), we were able to
demonstrate that the gp130-mediated inhibition of adipogenesis correlated most closely
with the activation of STAT1, but not STAT3. More significantly, we found that the
shRNA-mediated depletion of endogenous STAT1 protein served to largely attenuate the
inhibitory effects of either IL-11 or chimeric EpoR/gp130 receptor signaling on 3T3-L1
preadipocyte differentiation, as well as significantly rescue adipogenesis in the presence
of PGF2α. Taken together, therefore, our data provides evidence that STAT1 plays an
important role in mediating the inhibitory effects of the PGF2α/calcineurin-signaling
pathway on adipogenesis, where it appears to serve as a critical negative regulatory
effector downstream of gp130 receptor complexes to couple PGF2α/calcineurin-induced
autocrine IL-11 cytokine signaling-events to the inhibition of adipocyte differentiation
(see Fig. 15).
Our identification of STAT1 as a negative regulator of adipocyte differentiation is
consistent with prior studies that have suggested a potential role for STAT1 in mediating
the anti-adipogenic effects of IFNγ (McGillicuddy et al., 2009; Waite et al., 2001).
Interestingly, in contrast to the anti-adipogenic role of STAT1, other members of the
STAT transcription factor family, namely STAT3 and STAT5 (Richard and Stephens,
2011), have conversely been reported to play pro-adipogenic roles. In this regard, STAT3
has been proposed to play a role in promoting the expression of the early transcription
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factor C/EBPβ and is believed to play a critical role in the mitotic clonal expansion phase
of adipogenesis (Deng et al., 2000; Zhang et al., 2011), whereas STAT5 has been
reported to make a more direct contribution towards adipocyte differentiation by directly
helping promote the expression of PPARγ (Kawai et al., 2007; Nanbu-Wakao et al.,
2002). STAT proteins therefore play complex, diverse and opposing roles in the
regulation of adipocyte differentiation. By virtue of their established regulatory roles and
specific activation in response to diverse ligand-activated plasma membrane receptors
(Levy and Darnell, 2002; Levy and Darnell, 2002), STAT proteins offer the opportunity
to modulate and fine-tune the efficiency of the adipogenic process in response to
changing extracellular cues. However, exactly how the relative activities of these related
transcription factors are integrated at the level of the transcriptome to influence the
adipogenic cell fate decision remains to be determined.
Mechanistically, it is currently unclear how STAT1 activation results in the
inhibition of adipocyte differentiation. However, we believe that STAT1 likely acts at a
point proximal to the expression of the PPARγ master adipogenic transcription factor, as
our data shows that gp130 signaling is sufficient to attenuate the expression of PPARγ in
a STAT1-dependent manner, whereas ectopic expression of PPARγ2 is able to readily
bypass the inhibitory effects of gp130-mediated signaling (see Fig. 8). While STAT1 is
commonly thought to primarily play a role as a positively acting transcription factor, it is
evident that it can also act to inhibit transcriptional events in certain biological contexts
(Furukawa et al., 2009; Liu et al., 2008; Ramana et al., 2000). Hence, we envision that
STAT1 may contribute towards the inhibition of adipocyte differentiation via either of
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two non-mutually exclusive mechanisms. On the one hand, the most direct mechanism by
which STAT1 may inhibit adipogenesis is via the direct repression of a critical proadipogenic gene(s) that is required for adipogenesis. In this regard, it is perhaps
noteworthy that a nucleotide region capable of specifically binding STAT1 in vitro has
previously been identified in the immediate upstream regulatory region of the murine
PPARγ2 promoter and has been proposed to play a negative regulatory role in the
expression of this critical pro-adipogenic transcription factor (Hogan and Stephens,
2001), thereby raising the possibility that STAT1 may inhibit adipogenesis by directly
blocking the expression of PPARγ itself. Alternatively, STAT1 may contribute to the
inhibition of adipocyte differentiation via a more indirect mechanism in which STAT1 is
responsible for inducing the expression of a distinct anti-adipogenic gene(s) that is in turn
itself responsible for inhibiting the adipogenic process. In this respect, the increased
expression of many genes and microRNAs are known to be capable of inhibiting
adipogenesis by preventing expression of PPARγ (McGregor and Choi, 2011; Rosen and
MacDougald, 2006), although whether any of these known inhibitors act as functional
downstream anti-adipogenic effectors of STAT1 remains to be determined.
Consequently, the respective roles of either of these two non-mutually exclusive
pathways in mediating the STAT1-dependent inhibition of adipocyte differentiation and
the precise molecular mechanism(s) involved await further investigation.
Finally, while PGF2α has long been known to be a potent exogenous inhibitor of
adipocyte differentiation in vitro (Casimir et al., 1996; Lepak and Serrero, 1993; Liu and
Clipstone, 2007; Miller et al., 1996; Serrero et al., 1992), more recent data has
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FIGURE 15. Schematic model illustrating the proposed mechanism by which PGF2α
inhibits adipogenesis.

The PGF2α/calcineurin-signaling pathway induces IL-11 expression, which in turn binds
to the non-signaling IL-11Rα receptor subunit, recruits the gp130 co-receptor signaling
subunit and then, activates STAT1 transcription factor. It is the activation of STAT1
transcription factor that mediates the inhibitory effects of PGF2α on adipogenesis.
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highlighted an emerging in vivo role for PGF2α as an important endogenous negative
regulator of adipogenesis that is naturally synthesized by preadipocytes early during the
normal differentiation process, and appears to participate in an autocrine-mediated,
negative feedback loop that acts to restrict the overall adipogenic capacity of these cells
(Fujimori et al., 2010a; Fujimori et al., 2010b; Silvestri et al., 2013).We believe that this
latter negative feedback loop likely proceeds, at least in part, via the calcineurin/IL11/gp130/STAT1-mediated pathway that we have described here. In support of this
notion, we find that low levels of IL-11 are secreted in a calcineurin-dependent fashion
during the normal MDI-induced differentiation of 3T3-L1 preadipocytes, presumably in
response to the autocrine action of elevated levels of endogenously produced PGF2α.
Furthermore, we find that inhibition of the endogenous calcineurin/IL-11/gp130/STAT1
signaling pathway results in enhanced differentiation of 3T3-L1 preadipocytes, especially
under conditions of suboptimal adipogenic stimulation (Fig. 5 and Fig. 14). These results
therefore argue that this pathway represents an intrinsic negative regulatory feedback
mechanism that serves to restrict the differentiation of preadipocyte cells and thereby
plays a major role in determining the efficiency of the adipogenic process. Given the fact
that adipocyte-derived PGF2α production has been implicated as an important negative
regulator of adipose tissue expansion in vivo, involved in opposing the development of
obesity and its attendant diseases (Volat et al., 2012), it is tempting to speculate that these
effects, at least in part, are also mediated by this same calcineurin/IL-11/gp130/STAT1signaling module.

CHAPTER IV
THE PGF2α/CALCINEURIN-SIGNALING PATHWAY UPREGULATES
THE EXPRESSION OF THE ORPHAN NUCLEAR HORMONE RECEPTOR
NURR1 THROUGH A CRTC/CREB-DEPENDENT MECHANISM:
A POTENTIAL ROLE IN INHIBITING ADIPOCYTE DIFFERENTIATION

1. Introduction: In addition to the increased expression of the IL-11 cytokine
documented in the previous chapter, our microarray analysis revealed that the
PGF2α/calcineurin-signaling pathway also highly induced the expression of an orphan
nuclear hormone receptor, Nurr1 which is a member of the NR4A family of nuclear
hormone receptors which also includes Nur77 and Nor1. This was of interest as the
members of this family had previously been implicated in the negative regulation of
adipocyte differentiation. However, the role of Nurr1 in the PGF2α-mediated inhibition
of adipogenesis had not previously been investigated.

2. Nurr1 and its family members (NR4A Family):
2.1 Expression and functions of NR4A family members: Nurr1 and its related family
members are considered to be immediate early genes and are rapidly induced by a wide
variety of physiological stimuli, including cAMP, phorbol esters, prostaglandins,
calcium, fatty acids, stress and growth factors (Maxwell and Muscat, 2006; Pearen and
Muscat, 2010). They are expressed in multiple tissues including adipose tissue, skeletal
muscle,

kidney,

heart,

T-cells,

macrophages,
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liver

and

brain
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(Maxwell and Muscat, 2006; Pearen and Muscat, 2010). They are known to play a
diverse role in the regulation of cellular and physiological functions including a critical
role in metabolism, inflammation and vascular remodeling (McMorrow and Murphy,
2011; Zhao and Bruemmer, 2010). Importantly, Nurr1 is critical for the development of
dopaminergic neurons (Zetterstrom et al., 1997) and mutations in Nurr1 have been linked
to the development of Parkinson’s disease (Le et al., 2003; Sirin et al., 2010). Nurr1 has
also been shown to inhibit the proliferation of haematopoietic stem cells (Sirin et al.,
2010).

2.2 Role of Nurr1 and its family members in adipogenesis: While these receptors are
expressed at very low to undetectable levels in undifferentiated 3T3-L1 preadipocytes,
they are rapidly and transiently induced by MDI stimulation, reaching a peak level within
the first 4 h of the differentiation process, which then decreases to the basal level within
16 to 24 h (Fu et al., 2005; Soukas et al., 2001). Despite their rapid expression after
adipogenic stimulation, their exact role in normal adipogenic process is not known.
However, the over expression of Nurr1 and its family members are shown to inhibit
adipocyte differentiation (Chao et al., 2008). Conversely, Au et al (2008) suggested that
NR4A receptors are not required for adipogenesis, as the expression of a well
characterized-dominant-negative Nur77 that is known to block the function of all three
members Nur77, Nurr1 and Nor1 did not block adipogenesis (Au et al., 2008). While we
find that Nurr1 is highly induced by PGF2α during adipogenesis, its exact role in
mediating the inhibitory effects of PGF2α on adipogenesis is not known.
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2.3 Structure and regulation of Nurr1 activity: Like other nuclear hormone receptors,
NR4A family members contain a highly conserved central DNA binding domain, an Nterminal ligand-independent, AF-1 transactivation domain and a C-terminal ligandbinding, AF-2 transactivation domain (Maruyama et al., 1998). In contrast to other
nuclear hormone receptors, the crystal structure of Nurr1 shows that its ligand-binding
pocket is filled with bulky hydrophobic side chains and thus, it cannot be regulated by a
ligand (Flaig et al., 2005; Wang et al., 2003). In fact, the crystal structures show that
Nurr1 assumes the conformation of an active receptor even in the absence of a ligand
(Wang et al., 2003). Considering this observation, it seems that Nurr1 functions as a
constitutively active, ligand-independent receptor and its activity is primarily dependent
on its expression and posttranslational modifications. In fact, the mitogen-activated
protein kinase (ERK1, 2/ERK5) has been shown to positively regulate the transcriptional
activity of Nurr1 via phosphorylation of specific amino acids in the N-terminal AF-1
region, whereas LIM kinase 1 has been shown to negatively regulate Nurr1
transcriptional activity (Sacchetti et al., 2006). In addition, Nurr1 protein level has been
shown to be regulated by the ubiquitin-proteasome pathway via its N-terminal region.
Thus, the transcriptional activity of Nurr1 is regulated by multiple mechanisms (AlvarezCastelao et al., 2013).
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FIGURE 16. Schematic model showing the structure of Nurr1 and the modes of
regulation of gene expression by Nurr1.
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(A) Nurr1 contains an N-terminal AF-1 domain, a central DNA binding domain and a Cterminal AF-2 domain. (B-D) Nurr1 directly binds to DNA and regulates gene expression
as either monomer, homodimer or as a heterodimer with RxR. (E) Nurr1 indirectly
inhibits gene expression through interacting with the DNA bound NF-κB and recruitment
of co-repressor, CoREST.
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2.4 Regulation of gene expression by Nurr1 and its family members: NR4A family
members regulate gene expression as either monomers or homodimers by binding to
canonical DNA binding site called the nerve growth factor-induced protein B-responsive
element (NBRE) (Fig. 16B, C) (Maira et al., 1999; Paulsen et al., 1995; Philips et al.,
1997). Further, Nurr1 and Nur77 also heterodimerize with the retinoid X receptor (RXR)
and induce gene transcription by binding to DNA response elements composed of direct
repeats of consensus nuclear hormone response elements spaced by five nucleotides
called DR5 (Fig. 16D) (Perlmann and Jansson, 1995; Zetterstrom et al., 1997). While
Nurr1 has previously been shown to act as a positive transcription factor by inducing
gene expression via direct DNA binding to promoter regions (Davies et al., 2005; Lammi
et al., 2004; Sakurada et al., 1999), it is also clear that Nurr1 is able to repress the
expression of certain other genes (Kim et al., 2013; Kim et al., 2013; Mix et al., 2007;
Wu et al., 2005). In addition, the effects of Nurr1 do not always require it to directly bind
to DNA, as recent studies have indicated that Nurr1 can repress transcription of certain
genes indirectly by forming a complex with DNA-bound NF-κB and recruitment of
CoREST co-repressor complex (Fig. 16E) (Saijo et al., 2009).

2.5 Regulation of Nurr1 expression by the calcineurin phosphatase and the
CRTC2/CREB transcriptional complex: The Nurr1 promoter contains a consensus
cAMP response element (CRE) and has been shown to be regulated by the CREB
transcription factor in multiple cell types (Ji et al., 2012; McEvoy et al., 2002; Zhao et al.,
2011). Interestingly, CREB-induced Nurr1 expression is selectively regulated by the
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CRTC2 co-activator (Conkright et al., 2003). More importantly, CRTC2 is activated by a
cAMP and calcineurin-dependent mechanism (Screaton et al., 2004), as described later in
this chapter and Nurr1 expression is widely used as a marker to determine the activation
and the transcriptional regulation of CRTC2 (Conkright et al., 2003). In addition, a recent
study using hippocampal neurons shows that Nurr1 expression is regulated by an increase
in intracellular calcium through voltage-gated calcium channel and subsequent activation
of the calcium-dependent phosphatase, calcineurin (Tokuoka et al., 2014). Thus,
calcineurin appears to play a crucial role in the upregulation of Nurr1 expression in
multiple cell types.

3. CREB transcription factor: CREB belongs to the basic leucine zipper (bZIP) family
of transcription factors and is ubiquitously expressed in multiple tissues (Carlezon et al.,
2005; Shaywitz and Greenberg, 1999). It is activated by a diverse array of extracellular
stimuli including peptide hormones, growth factors, osmotic stress, ultraviolet irradiation
and neuronal activity (Carlezon et al., 2005; Shaywitz and Greenberg, 1999). The
transcriptional activity of CREB is regulated by the phosphorylation of serine 133 by
different serine-threonine kinases including cAMP-dependent protein kinase A (PKA),
protein kinase C (PKC), calmodulin kinases (CaMKs) and ribosomal S6 kinase
(Gonzalez and Montminy, 1989; Gubina et al., 2001; Seamon et al., 1981; Sheng et al.,
1991; Xing et al., 1996). Once CREB is phosphorylated on serine 133, it dimerizes, binds
to its co-activators, CREB-binding protein (CBP) or p300 (Arias et al., 1994; Chrivia et
al., 1993; Kwok et al., 1994) and, then induces the expression of its target genes through
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binding to CREB-responsive element (CRE), which consist of either palindromic (5’TGACGTCA-3’) or half-site (TGACG or CGTCA) sequences (Comb et al., 1986;
Montminy et al., 1986).
CREB plays a diverse role in the regulation of various physiological and
pathological process including cell differentiation, glucose and lipid metabolism in liver,
immune function, cell survival in neurons and pancreatic β-cells, consolidation of
memory, cancer progression and others (Carlezon et al., 2005; Herzig et al., 2001; Herzig
et al., 2003; Hong et al., 2005; Pittenger et al., 2002; Wen et al., 2010). More importantly,
CREB is constitutively expressed in preadipocytes (Reusch et al., 2000) and plays
multiple roles during adipocyte differentiation by regulating the expression of several
genes involved in adipogenesis, which is discussed in the chapter I of this dissertation.

4. CRTC family of transcriptional co-activators: The CRTC proteins are a family of
recently identified co-activators of the CREB transcription factor and consist of three
members: CRTC1, CRTC2 and CRTC3 (Conkright et al., 2003; Iourgenko et al., 2003).
CRTC1 is highly expressed in brain, whereas CRTC2 and CRTC3 are abundantly
expressed in multiple tissues (Conkright et al., 2003). Under basal conditions, CRTCs are
highly phosphorylated and retained in the cytoplasm by interactions with 14-3-3 adaptor
protein (Screaton et al., 2004). Specifically, CRTC2 is highly phosphorylated at serine
171 and 275 by salt inducible kinase (SIK1) and MARK1, respectively (Screaton et al.,
2004). The phosphorylation of these residues form docking site for 14-3-3 adaptor
proteins, thereby CRTC2 is retained in the cytoplasm in an inactive form. However, when
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FIGURE 17. Schematic model showing the activation of the CRTC2 co-activator.

Under basal conditions, CRTC2 is highly phosphorylated and retained in the cytoplasm
by the 14-3-3 adaptor protein. Upon stimulation with appropriate stimuli, CRTC2 is
dephosphorylated by a cAMP and calcineurin-dependent mechanism and subsequently,
translocates into the nucleus, where it interacts with CREB and enhances the
transcriptional activity of the CREB.

100
the cells are stimulated with appropriate stimuli, SIK1 is inactivated by PKA-dependent
inhibitory phosphorylation, whereas calcineurin dephosphorylates serine 275 (Screaton et
al., 2004). The dephosphorylation of CRTC2 by these two mechanisms releases it from
14-3-3 adaptor proteins, resulting in the translocation of CRTC2 to nucleus where it binds
to the bZIP domain of CREB and promote the transcriptional activity of CREB (Fig. 17)
(Screaton et al., 2004). In fact, CRTCs do not modulate the DNA binding ability of
CREB, but rather enhance the transcriptional activity of CREB by augmenting it’s
interaction with the TAFII130 component of transcription factor II D (TFIID) (Conkright
et al., 2003). More importantly, CRTCs regulate the transcriptional activity of CREB in a
canonical serine 133 phosphorylation-independent mechanism. The activity of CRTC2 is
terminated by the prolyl-isomerase Pin1, which interacts with serine 136 in the nuclear
localization signal of CRTC2 and promotes its export from the nucleus to cytosol
(Nakatsu et al., 2010).
CRTCs are known to regulate a variety of biological processes. CRTC1 regulates
satiety, circadian clock, snaptic plasticity and memory in the brain (Sakamoto et al.,
2013; Sekeres et al., 2012; Zhou et al., 2006), whereas CRTC2 and CRTC3 are primarily
involved in the regulation of metabolism in the liver and adipose tissue (Dentin et al.,
2007; Song et al., 2010; Wang et al., 2012). In the liver, CRTC2 is highly phosphorylated
in response to insulin, resulting in its nuclear exclusion and degradation (Dentin et al.,
2007), whereas glucagon causes dephosphorylation and nuclear translocation of CRTC2,
resulting in the expression of gluconeogenic genes (Wang et al., 2012). CRTC3 has been
shown to attenuate the β-adrenergic receptor signaling in adipose tissue by upregulating
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the expression of regulator of G-protein signaling 2 (Rgs2) (Song et al., 2010). While the
CRTC proteins are shown to play a diverse role in multiple tissues, their role in adipocyte
differentiation is not known.
In this chapter, we investigated the molecular mechanism by which the
PGF2α/calcineurin-signaling pathway induces Nurr1 expression during adipocyte
differentiation and the functional significance of increased Nurr1 expression in mediating
the inhibitory effect on adipogenesis. First, we show that PGF2α upregulates the
expression Nurr1 in a calcineurin-dependent fashion. Next, we show that the expression
of a dominant-negative Nurr1 partially rescues adipogenesis from the inhibitory effects of
PGF2α. Then, using a panel of Nurr1 mutants, we demonstrate that the direct DNA
binding of Nurr1, but not its heterodimerization with RxR is required to inhibit
adipogenesis. In addition, using a panel of CREB mutants and the shRNA approach, we
demonstrate that PGF2α-mediated activation of the CRTC/CREB transcriptional complex
induces

Nurr1

expression.

Collectively,

these

results

demonstrate

that

the

PGF2α/calcineurin-signaling pathway inhibits adipogenesis by inducing the expression of
Nurr1 through activation of the CRTC/CREB-transcriptional complex.

5. RESULTS
5.1 The PGF2α/calcineurin-signaling pathway induces Nurr1 expression in
differentiating 3T3-L1 preadipocytes: Our previous studies showed that PGF2α
inhibits adipocyte differentiation through a calcium-dependent phosphatase calcineurin
(Liu and Clipstone, 2007), which is well-known to regulate gene expression through
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FIGURE 18. The PGF2α/calcineurin-signaling pathway induces Nurr1 expression,
but not other family members during adipocyte differentiation.

Two-day post confluent 3T3-L1 preadipocytes were induced to undergo adipocyte
differentiation by treatment with MDI in the presence of either vehicle, PGF2α (25 nM)
alone or PGF2α (25 nM) plus cyclosporine A (CsA) (1 µg/ml). At 48 h post-stimulation,
total RNA and total cell lysates were collected. (A) The expression of Nurr1 and Nur77
was determined by qRT-PCR and (B) Nurr1 expression was determined by
immunoblotting. The data is shown as mean ± SEM (one-way ANOVA followed by
Bonferroni post hoc test; p<0.05; n=3). Results are representative of at least three
independent experiments.
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activation of various transcriptional regulators. As previously discussed, we performed an
initial microarray experiment to identify the potential downstream effectors of the
PGF2α/calcineurin-signaling pathway during adipogenesis. In addition to the IL-11
cytokine discussed in the chapter III, our analysis also identified an orphan nuclear
hormone receptor, Nurr1 as one of the most highly induced genes by the
PGF2α/calcineurin-signaling pathway during adipogenesis. This was of interest, as Nurr1
and its family members are known to play a role in the regulation of cell differentiation
and development, and their over expression has previously been shown to inhibit
adipocyte differentiation (Chao et al., 2008).
To confirm the initial microarray data, 3T3-L1 cells were induced to differentiate
with the MDI-induced differentiation protocol in the presence or absence of PGF2α or
pretreatment with the calcineurin inhibitor, CsA. At 48 h post-induction, mRNA and
protein were collected for qRT-PCR and immunoblotting, respectively. During
adipogenesis, Nurr1 expression was undetectable with MDI alone, whereas PGF2α
significantly induced Nurr1 expression at both the mRNA and protein level at 48 h poststimulation (Fig. 18A, B). Importantly, the PGF2α-induced Nurr1 expression was
attenuated to the basal level with CsA pretreatment, which indicates a role of calcineurin
in mediating the PGF2α-induced Nurr1 expression during adipogenesis. Interestingly,
another family member Nur77 was not significantly induced by PGF2α and Nor1 was
undetectable with four different primer pairs. Collectively, these results demonstrate that
PGF2α selectively upregulates Nurr1 expression through the activation of the calcineurin
phosphatase.
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5.2 Nurr1 plays a potential role in mediating the inhibitory effects of PGF2α on
adipocyte differentiation: Having shown that PGF2α induces Nurr1 expression during
adipogenesis, we next determined whether Nurr1 is necessary for PGF2α to inhibit
adipocyte differentiation. To accomplish this, we initially tried to stably knockdown the
expression of Nurr1 in 3T3-L1 cells using shRNA approach. However, our attempts to
deplete the expression of Nurr1 by several shRNAs were unsuccessful. Hence, we took
advantage of a dominant-negative mutant that is known to inhibit the activity of all three
members of NR4A2 family of orphan nuclear receptors. This dominant-negative mutant
contains the DNA binding domain of Nurr1 fused with the transcriptional repressor
domain of the KRAB repressor (DN-Nurr1; Fig. 19A). First, we determined whether this
DN-Nurr1 is functional by transient transfection luciferase reporter gene assay in
HEK293T cells. As described in the materials and methods, we transfected these cells
with equal concentrations of plasmid encoding wild-type Nurr1 (Nurr1-WT) and
increasing concentrations of DN-Nurr1 plasmids. Simultaneously, the cells were also
transfected with the Nurr1 reporter, (NBRE)3-TK-LUC and pRG-TK reporter plasmids.
At 24 h post-transfection, cell lysates were prepared and the luciferase bioluminescence
was determined. As shown in Figure 19B, Nurr1-WT expression showed a maximal
luciferase activity, whereas there was a dose-dependent inhibition of Nurr1-WT activity
by DN-Nurr1 as measured by the luciferase activity. This demonstrates that the DNNurr1 is functional and it inhibits the transcriptional activity of the wild-type Nurr1.

105

106
FIGURE 19. Evidence that Nurr1 potentially plays a role in mediating the inhibitory
effects of PGF2α on adipogenesis.

(A) Schematic model illustrating the dominant-negative Nurr1 (DN-Nurr1). (B)
HEK293T cells were transfected with Nurr1-WT (100 ng) and increasing concentrations
of DN-Nurr1 (0, 100, 200 and 400 ng) along with (NBRE)3-TK-Luc (50 ng) and pRGTK (25 ng) reporter plasmids. At 24 h post-transfection, luciferase assay was performed
and the percent maximal luciferase activity was calculated. (C, D) 3T3-L1 preadipocytes
transduced with either MSCV-GFP or DN-Nurr1 encoding retroviruses were induced to
differentiate with MDI in the presence of the indicated concentrations of PGF2α for the
initial 48 h and the extent of adipogenesis was determined at day 8 by either ORO
staining (C) or immunoblotting for the expression of PPARγ and ERK as a control for
equal loading (D). Results are representative of three independent experiments.
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Next, to determine whether Nurr1 is involved in the PGF2α-mediated inhibition
of adipocyte differentiation, we tested whether the ectopic expression of the DN-Nurr1
mutant was able to rescue cells from the inhibitory effects of PGF2α on adipogenesis.
We expressed either MSCV-GFP or DN-Nurr1 in 3T3-L1 cells using retroviruses and
induced these cells to differentiate by the MDI-induced differentiation protocol in the
presence of increasing concentrations of PGF2α. As shown in Figure 19C, D, the
differentiation of the control GFP-expressing cells was inhibited by PGF2α in a
concentration-dependent fashion as evidenced by the decreased ORO staining and the
decreased expression of PPARγ. Conversely, we observed a partial rescue of
differentiation in DN-Nurr1 expressing cells at the concentration of PGF2α that clearly
inhibited differentiation of control GFP expressing cells, which is evident from the
increased ORO staining and the increased expression of PPARγ (Fig. 19C, D) These
results demonstrate that Nurr1 is indeed required for mediating the inhibitory effects of
PGF2α on adipogenesis.

5.3 Nurr1-mediated inhibition of adipogenesis requires its direct DNA binding: The
over expression of Nurr1 has previously been shown to inhibit adipocyte differentiation
(Chao et al., 2008). Hence, we decided to use Nurr1-WT as a positive control in our
experiments. Similar to the previous findings, the ectopic expression of Nurr1-WT
inhibited adipogenesis, which is evidenced by the decreased ORO staining and the
decreased expression of PPARγ (Fig. 20C, D). Furthermore, the ectopic expression of
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FIGURE 20. Ectopic expression of Nurr1 inhibits adipogenesis via a DNA binding
and RXR-independent mechanism.

(A) Schematic model showing the Nurr1 mutants and their ability to bind to either DNA
or RxR. (B) 3T3-L1 preadipocytes were infected with either MSCV-GFP, Nurr1-WT,
Nurr1-AA or Nurr1-KLL encoding retroviruses and their expression was determined by
immunoblotting with an antibody specific for Nurr1, while equal protein loading was
confirmed by immunoblotting with a control antibody directed against ERK. (C, D) Twoday post-confluent cells were induced to differentiate by the standard MDI-induced
protocol. After 8 days, adipocyte differentiation was assessed by ORO staining (C) and
immunoblotting for the expression of PPARγ, aP2 and ERK as a control for equal loading
(D). (E) 3T3-L1 cells were initially infected with either MSCV-GFP or Nurr1-WT
encoding retroviruses and then super-infected with either MSCV-Ds-Red or MSCV-DsRed-PPARγ encoding retroviruses, as indicated. Two-day post-confluent cells were
induced to differentiate by standard MDI-induced differentiation protocol. After 8 days,
the adipogenesis was determined by ORO staining. Results in (B, C & D) are
representative of four independent experiments, whereas results in (E) are representative
of two independent experiments.
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PPARγ in these cells was able bypass the inhibitory effect of Nurr1-WT on adipogenesis
(Fig. 20E). Taken together, these results demonstrate that Nurr1 is sufficient to inhibit
adipocyte differentiation, most likely by a mechanism that is proximal to the expression
of pro-adipogenic transcription factor, PPARγ.
Having shown that Nurr1 expression is sufficient to inhibit adipogenesis and
plays a role in mediating the inhibitory effect of PGF2α on adipocyte differentiation, we
decided to gain insights into the mechanism by which Nurr1 mediates its inhibitory effect
on adipogenesis. Being a transcription factor, Nurr1 most commonly regulates gene
expression by directly binding to DNA (Lammi et al., 2004; Sakurada et al., 1999).
However, Nurr1 has recently been shown to indirectly transrepress gene expression by
interacting with DNA-bound NFκB and promoting the recruitment of transcriptional corepressor complex (Saijo et al., 2009). Hence, in order to determine whether Nurr1
interacts directly or indirectly with DNA to inhibit adipogenesis, we took advantage of
the previously well-characterized mutant form of Nurr1 that is unable to bind the DNA,
Nurr1-AA with C280A and E281A mutations in DNA binding domain (Fig.20A) (Saijo
et al., 2009). We expressed this mutant in 3T3-L1 cells by retroviral transduction system
and initially determined that this mutant was expressed to a level comparable to that of
Nurr1-WT expression (Fig.20B). Then, we induced these cells to undergo adipogenesis
with the standard MDI-induced differentiation protocol. As shown in Figure 20C, D,
while Nurr1-WT expression inhibited adipogenesis as described earlier, Nurr1-AA
expressing cells completely differentiated into mature adipocytes as evidenced by the
increased ORO staining and the increased expression of adipocyte specific genes PPARγ
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and aP2. This shows that the ability of Nurr1 to inhibit adipocyte differentiation is strictly
dependent upon its ability to directly bind to DNA.

5.4

Nurr1-mediated

inhibition

of

adipogenesis

does

not

require

its

heterodimerization with RXR: Nurr1 is known to regulate gene expression as
monomer, homodimer or heterodimer with RXR (Maxwell and Muscat, 2006). Hence, to
determine whether the heterodimerization of Nurr1 with RXR is required to inhibit
adipogenesis, we took advantage of the previously well-characterized mutant form of
Nurr1 that cannot heterodimerize with RXR, Nurr1-KLL with K555A, L556A and
L557A mutation (Fig.20A) (Aarnisalo et al., 2002). We expressed the Nurr1-KLL mutant
in 3T3-L1 cells and initially determined that it was expressed to a comparable level to
that of Nurr1-WT expression (Fig.20B). When these cells were induced to undergo
adipogenesis with MDI, similar to Nurr1-WT expressing cells, Nurr1-KLL expressing
cells failed to differentiate into mature adipocytes, which is evident from the decreased
ORO staining and the decreased expression of PPARγ and aP2 (Fig. 20C, D). This
demonstrates that Nurr1 does not require its heterodimerization with RXR to inhibit
adipocyte differentiation.

5.5 CREB and its association with CRTC2 are required for PGF2α-mediated Nurr1
expression during adipocyte differentiation: Having shown that Nurr1 is induced by
the PGF2α/calcineurin-signaling pathway and plays a role in mediating the inhibitory
effect of PGF2α on adipogenesis, we next sought to determine the signaling mechanism
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FIGURE 21. PGF2α induces Nurr1 expression through CREB-dependent
mechanism during adipogenesis.

3T3-L1 cells transduced with either MSCV-GFP, K-CREB or CREB R314A encoding
retroviruses were induced to undergo differentiation with MDI in the presence or absence
of PGF2α (25 nM) and mRNA was collected at 48 h post-induction. Nurr1 expression
was determined by qRT-PCR. The data is shown as mean ± SEM (one-way ANOVA
followed by Bonferroni post hoc test; p<0.05; n=3). Results are representative of two
independent experiments.
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by which Nurr1 expression is regulated by this pathway. In this regard, the Nurr1
promoter contains a CREB responsive element (CRE) and has been shown to be
regulated by the CREB transcription factor in different cell types (Ji et al., 2012; McEvoy
et al., 2002; Zhao et al., 2011). Interestingly, the CREB-induced Nurr1 expression is
selectively regulated by a recently identified transcriptional co-activator, CRTC2
(Conkright et al., 2003). More importantly, CRTC2 is dephosphorylated and activated by
the calcineurin phosphatase and then, it translocates into the nucleus and regulates the
CREB transcriptional activity (Screaton et al., 2004). Hence, we sought to determine
whether CREB and its association with CRTC2 are required for PGF2α to induce Nurr1
expression. To determine this, we took advantage of two well-characterized CREB
mutants, K-CREB that blocks DNA binding of endogenous CREB and CREB R314A
that blocks the direct interaction of CREB with CRTC2 (Walton et al., 1992; Xu et al.,
2007). Thus, K-CREB prevents induction of CREB regulated genes and CREB R314A
blocks the expression of CRTC2-regulated CREB-induced genes. We introduced either
control MSCV-GFP or the CREB mutants independently by retroviral transduction into
3T3-L1 cells and induced these cells to differentiate with MDI in the presence or absence
of PGF2α. At 48 h post-induction, mRNA was collected to determine the Nurr1
expression by qRT-PCR. As shown in Figure 21, while PGF2α significantly increased the
expression of Nurr1 in control GFP expressing cells, ectopic expression of either
K-CREB or CREB R314A significantly attenuated the PGF2α-induced Nurr1 expression
during the early stages of adipogenesis. These results demonstrate that CREB, and more
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specifically, its interaction with CRTC2 are required for the PGF2α-induced Nurr1
expression during adipocyte differentiation.

5.6 The PGF2α/calcineurin-signaling pathway induces the activation and nuclear
translocation of CRTC2 co-activator during adipogenesis: Since calcineurin is known
to activate CRTC2 and the CREB mutant that cannot interact with CRTC2 blocks the
PGF2α-induced

Nurr1

expression,

we

decided

to

determine

whether

the

PGF2α/calcineurin-signaling pathway induces the activation and nuclear translocation of
CRTC2 during adipogenesis. Initially, we attempted to determine the activation of the
endogenous CRTC2 protein using a variety of commercially available antibodies.
However, due to the poor quality of antibodies, we were unable to successfully determine
the activation of the endogenous CRTC2. Hence, we used an YFP tagged CRTC2 to
detect it’s activation by this pathway using immunofluorescence method. We expressed
the YFP-CRTC2 in 3T3-L1 cells using retroviruses and induced these cells to undergo
adipocyte differentiation with MDI in the presence or absence of PGF2α or pretreatment
with the calcineurin inhibitor, CsA. As shown in Figure 22A and B, MDI alone induced a
transient cytoplasmic to nuclear translocation of YFP-CRTC2 during the very early stage
of adipocyte differentiation. In contrast, PGF2α induced a sustained nuclear translocation
of YFP-CRTC2 for a prolonged period of time. This sustained translocation of CRTC2
into the nucleus by PGF2α was abolished by the pretreatment with a calcineurin
inhibitor, CsA. This demonstrates that PGF2α induces a sustained cytoplasmic to nuclear
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FIGURE 22. The PGF2α/calcineurin-signaling pathway induces sustained activation
of CRTC2.
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(A, B) 3T3-L1 preadipocytes transduced with YFP-CRTC2 encoding retrovirus was
induced to differentiate with MDI in the presence of either vehicle, PGF2α (25 nM) alone
or PGF2α (25 nM) plus CsA (1 µg/ml). The nuclear translocation of YFP-CRTC2 was
determined by immunofluorescence at the indicated time points (A) and the percentage of
cells with nuclear YFP-CRTC2 was calculated (B). The data is shown as mean ± SEM
(One-way ANOVA followed by Bonferroni post hoc test; p<0.05; n=3). Results are
representative of three independent experiments.
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translocation of CRTC2 co-activator through a calcineurin-dependent pathway during
adipogenesis.
5.7 PGF2α requires the CRTC proteins to induce Nurr1 expression during
adipogenesis: Having shown that CRTC2 co-activator is activated by the
PGF2α/calcineurin-signaling pathway, we next sought to determine whether CRTC2 is
indeed required for PGF2α to induce Nurr1 expression during adipogenesis. Hence, we
attempted to stably deplete the expression of CRTC2 by shRNA approach. Initially, we
expressed either control shLUC or CRTC2 shRNA in 3T3-L1 cells using retroviruses and
collected mRNA from the confluent cells to determine the knockdown efficiency of the
shRNA by qRT-PCR. As shown in Figure 23A, the expression of CRTC2 was
significantly inhibited by the CRTC2 shRNA. Unexpectedly, this shRNA also inhibited
the expression of another family member, CRTC1 due to the fact that this shRNA
partially recognizes the CRTC1 mRNA (Fig. 23C). Next, we determined the expression
of Nurr1 in these cells in response to PGF2α during adipogenesis. As shown in Figure
23C, the control shLUC and CRTC2 shRNA expressing cells were induced to
differentiate with MDI-induced differentiation protocol in the presence or absence of
PGF2α and mRNA was collected at 48 h post-induction for qRT-PCR. As expected,
while Nurr1 expression was significantly increased in response to PGF2α in control
shLUC cells, the stable depletion of CRTC expression significantly attenuated Nurr1
expression in response to PGF2α. This demonstrates that CRTC proteins are required for
the PGF2α-induced Nurr1 expression during adipocyte differentiation.

118

C.

FIGURE 23. CRTC co-activators are required for the PGF2α to induce Nurr1
expression during adipocyte differentiation.

(A, B) 3T3-L1 cells infected with either control shLUC or CRTC2 shRNA encoding
retroviruses were induced to differentiate with MDI in the presence or absence of PGF2α
(25 nM) and the mRNA was collected at 0 and 48 h post-induction. The shRNA-specific
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knockdown efficiency at 0 h (A) and Nurr1 expression at 48 h post-stimulation (B) were
determined by qRT-PCR. The data is shown as mean ± SEM (either student’s t test or
one-way ANOVA followed by Bonferroni post hoc test; p<0.05; n=3). Results are
representative of two independent experiments. (C) Necleotide alignment of CRTC2
shRNA with the coding sequences of CRTC2 and CRTC1.
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5.8 CRTC2 activity is sufficient to induce Nurr1 expression and to inhibit adipocyte
differentiation: Having shown that CRTC2 is activated by PGF2α and CRTC proteins
are required for the PGF2α-induced Nurr1 expression, we decided to determine whether
CRTC2 is sufficient to induce Nurr1 expression in differentiating 3T3-L1 cells. Hence,
we generated a constitutively active CRTC2 (caCRTC2) by mutating the critical serine
residues required for its cytoplasmic retention to alanine (S171A and S275A). Then, the
caCRTC2 was fused to the hormone binding domain of estrogen receptor (ER-caCRTC2;
Figure 24A), thereby CRTC2 activity can be conditionally activated in response to
tamoxifen. First, as described in the materials and methods, we determined the
conditional activation of ER-caCRTC2 by transient transfection luciferase reporter assay
in HEK293T cells using a well characterized CREB reporter, CRE-Luc. As shown in
Figure 24B, while luciferase activity was minimal in control GFP and untreated ERcaCRTC2 cells, tamoxifen treatment was able to significantly induce the luciferase
activity in ER-caCRTC2 expressing cells. This shows that ER-caCRTC2 is functional
and its activity can be selectively regulated by tamoxifen. Next, to determine whether the
conditional activation of CRTC2 is sufficient to induce Nurr1 expression, we expressed
either MSCV-GFP or ER-caCRTC2 in 3T3-L1 cells using retroviruses and induced these
cells to differentiate using MDI in the presence or absence of tamoxifen. At 48 h postinduction, mRNA was collected to determine the Nurr1 expression by qRT-PCR. As
shown in Figure 24C, Nurr1 was not induced by tamoxifen treatment in control GFP
expressing cells. In contrast, Nurr1 expression was significantly increased in ERcaCRTC2 cells in the presence of tamoxifen compared to MDI alone. This shows that the
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FIGURE 24. Conditional and selective activation of the constitutively active CRTC2
is sufficient to induce Nurr1 expression and to inhibit adipogenesis.

(A) Schematic model showing the tamoxifen inducible, constitutively active CRTC2
(ER-caCRTC2). (B) HEK293T cells were transfected with ER-caCRTC2 plasmid (400
ng) along with CRE-Luc (50 ng) and pRG-TK (25 ng) reporter plasmids. After 16 h posttransfection, cells were treated with tamoxifen and luciferase activity was determined at
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4 h post-treatment. (C, D & E) 3T3-L1 cells transduced with either GFP or ER-caCRTC2
retroviruses were induced to differentiate with MDI in the presence or absence of
tamoxifen (1 µM). At 48 h post induction, mRNA was collected and Nurr1 expression
was determined by qRT-PCR (C). After 8 days, adipocyte differentiation was determined
by ORO (D) and immunobloting for the expression of PPARγ, aP2 and ERK as a loading
control for equal loading (E). The data is shown as mean ± SEM (One-way ANOVA
followed by Bonferroni post hoc test; p<0.05; n=3). Results are representative of three
independent experiments.
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selective activation of CRTC2 is sufficient to induce Nurr1 expression during
adipogenesis.
Next, having demonstrated that the activation of ER-caCRTC2 is sufficient to
induce Nurr1 expression, we also determined whether the activation of ER-caCRTC2 is
sufficient to inhibit adipogenesis. Hence, the control GFP or ER-caCRTC2 cells were
stimulated to undergo adipogenesis with MDI-induced differentiation protocol in the
presence or absence of tamoxifen for the initial 48 h. As shown in Figure 24D and E,
control GFP expressing cells differentiated into adipocytes in the presence of tamoxifen.
In contrast, while ER-caCRTC2 expressing cells differentiated into adipocytes with MDI
alone, the selective activation of ER-caCRTC2 using tamoxifen inhibited adipogenesis,
which is evident from the decreased ORO staining and the diminished expression of
PPARγ and aP2 (Fig. 24D,E). This demonstrates that the selective activation of CRTC2
is sufficient to inhibit adipogenesis and thus, phenocopies the inhibitory effects of PGF2α
on adipocyte differentiation. Collectively, our results demonstrate that the sustained
activation of CRTC2, similar to PGF2α, is sufficient to induce Nurr1 expression and to
inhibit adipocyte differentiation.

5.9 CRTC co-activator proteins play a critical role in the regulation of normal
adipocyte differentiation: Having shown that CRTC co-activator proteins, more
specifically CRTC2, are required for the PGF2α-induced Nurr1 expression and that
CRTC2 activation is sufficient to inhibit adipogenesis, we next sought to directly
determine whether CRTC protein is required for the PGF2α-mediated inhibition of
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FIGURE 25. CRTC is required for normal adipocyte differentiation.

3T3-L1 cells were initially infected with either control shLUC or CRTC2 shRNA
encoding retroviruses and then super-infected with either Ds-Red or Ds-Red PPARγ
retroviruses, as indicated. Two-day post-confluent cells were induced to differentiate with
MDI and adipogenesis was determined after 8 days of induction by ORO (A). (B, C)
3T3-L1 preadipocytes infected with either control shLUC or CRTC2 shRNA encoding
retroviruses were induced to differentiate with MDI and the cell lysates were collected at
the indicated times after adipogenic stimulation and, immunoblotting was performed for
C/EBPβ, C/EBPδ, C/EBPα, PPARγ, aP2 and ERK as a loading control. The results in
(A) are representative of three independent experiments, whereas the results in (B, C) are
representative of two independent experiments.
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adipogenesis. To accomplish this, we investigated the ability of CRTC depleted cells to
differentiate in the presence of PGF2α. We induced either the control shLUC or CRTC2
shRNA expressing cells to differentiate using MDI-induced differentiation protocol in the
presence or absence of PGF2α for the initial 48 h. Surprisingly, while control shLUC
expressing cells completely differentiated into adipocytes, stable depletion of CRTC
expression inhibited the ability of the cells to undergo adipocyte differentiation in the
presence of MDI alone, as evidenced by the decreased ORO staining and the decreased
expression of adipocyte specific genes PPARγ and aP2 (Fig. 25A, B). Hence, we were
unable to dissect the role of CTRC in mediating the inhibitory effects of PGF2α on
adipogenesis. However, this provided surprising evidence that the CRTC co-activators
play a crucial positive regulatory role in the normal adipogenic process. Further, the
ectopic expression of PPARγ in the CRTC2 shRNA expressing cells rescued their
potential to differentiate into mature adipocytes (Fig. 25A), suggesting that CRTC
regulates a critical step(s) proximal to the expression of PPARγ during normal adipocyte
differentiation process. To further understand the underlying mechanisms, we determined
the expression of key adipogenic transcription factors in the CRTC2 shRNA expressing
cells during adipogenesis. As shown in Figure 25B and C, while the expression of the late
transcription factors, C/EBPα and PPARγ and the early transcription factor, C/EBPβ
were not affected by the depletion of CRTC protein expression, the expression of the
early transcription factor C/EBPδ was decreased in these cells, suggesting that CRTC
proteins might play a critical role in the regulation of C/EBPδ. Collectively, our results
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demonstrate that CRTC proteins are required for normal adipocyte differentiation process
and possibly, they regulate the expression of early transcription factor, C/EBPδ.

6. DISCUSSION
In this dissertation chapter, we further investigated the mechanism by which
PGF2α inhibits adipocyte differentiation and provide evidence that the increased
expression of Nurr1 plays an important role in mediating the inhibitory effects of the
PGF2α/calcineurin-signaling pathway on adipogenesis. Further, we have established that
PGF2α induces Nurr1 expression via the calcineurin-dependent activation of CRTC
proteins and the subsequent activation of the CREB transcription factor. Collectively, our
results provide evidence that in addition to the IL-11/gp130/STAT1-signaling pathway
described in chapter III, PGF2α can also inhibit adipogenesis by the means of a
calcineurin/CRTC/CREB/Nurr1-dependent signaling mechanism.
While all the members of the NR4A family of transcription factors are known to
be transiently expressed in 3T3-L1 cells during the initial few hours of adipogenesis and
in response to various inflammatory mediators in different cell types (Chao et al., 2008;
Pei et al., 2005), we found that PGF2α induces a sustained and prolonged expression of
Nurr1. Interestingly, while PGF2α highly upregulates the expression of Nurr1, other
family members Nur77 and Nor1 are not induced by PGF2α. More importantly, this
increased PGF2α-induced Nurr1 expression was completely abrogated to the basal level
with the inhibition of the calcineurin phosphatase activity, which demonstrates that
PGF2α induces a sustained expression of Nurr1 via activation of the calcineurin
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phosphatase. This is consistent with a recent finding in hippocampal neurons
demonstrating that calcineurin plays an important role in Nurr1 expression in these cells
(Tokuoka et al., 2014). Thus, our results demonstrate that Nurr1 is a selective
transcriptional target of the PGF2α/calcineurin-signaling pathway during the early stages
of adipogenesis.
While the ectopic expression of Nurr1 has previously been shown to inhibit
adipocyte differentiation (Chao et al., 2008), we find that the PGF2α/calcineurinsignaling pathway induces a sustained expression of endogenous Nurr1. Further, the
transient activation of its family member Nur77 has previously been shown to positively
regulate adipogenesis, whereas the prolonged ectopic expression of Nur77 has been
shown to inhibit adipogenesis (Fumoto et al., 2007). In our studies, while PGF2α inhibits
adipogenesis, it also induces a sustained expression of endogenous Nurr1. Hence, our
initial hypothesis was that the increased endogenous Nurr1, in addition to IL-11, mediates
the inhibitory effects of PGF2α on adipogenesis. The direct evidence to support this
hypothesis came from our observation that the expression of a dominant-negative Nurr1
was able to partially rescue adipogenesis from the inhibitory effects of PGF2α. This
shows that the sustained expression of endogenous Nurr1 plays a critical role in
mediating the inhibitory effects of PGF2α on adipogenesis. However, the mechanism by
which Nurr1 inhibits adipogenesis and how the dominant-negative Nurr1 functions to
rescue adipogenesis is unclear. It is possible that the dominant-negative Nurr1 binds to
DNA and blocks the interaction of the endogenous Nurr1 to DNA. Alternatively, the
dominant-negative Nurr1 may dimerize with the endogenous Nurr1, bind to DNA and
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block gene expression through its KRAB repressor domain. Since, we observe a partial
rescue from PGF2α by expressing the dominant-negative Nurr1 with KRAB repressor
domain, we predict that most likely the dominant-negative Nurr1 acts to prevent the
expression of a gene(s) that is induced by the sustained expression of endogenous Nurr1.
In this respect, Nurr1 has been shown to induce the cell cycle inhibitor p18 and inhibit
the proliferation of the haematopoietic stem cells (Sirin et al., 2010). However, while
there is a possibility that Nurr1 could inhibit adipogenesis by blocking the mitotic clonal
expansion by the similar mechanism, our previous studies demonstrate that PGF2α does
not inhibit mitotic clonal expansion (Liu and Clipstone, 2007). Hence, we feel that Nurr1
might induce some other anti-adipogenic gene or microRNA to inhibit adipocyte
differentiation. In contrast, since Nurr1 has also been shown to repress gene expression
in multiple cell types (Jacobs et al., 2009; Kim et al., 2013), it is also possible that Nurr1
may also directly repress the expression of critical genes involved in adipogenesis.
Having provided evidence that Nurr1 is induced and plays a role in mediating the
inhibitory effects of the PGF2α/calcineurin-signaling pathway on adipogenesis, we were
then interested to understand the potential mechanisms by which Nurr1 inhibits
adipogenesis. Nurr1 has been shown to regulate gene expression as either monomer,
homodimer or as a heterodimer with its partner protein RXR (Maxwell and Muscat,
2006). Initially, the heterodimerization of Nurr1 with RXR has caught our attention, as
the master regulator of adipogenesis PPARγ also requires RXR to induce gene expression
(Palmer et al., 1995). Thus, it raised a possibility that the sequestration of RxR by Nurr1
might inhibit the availability of RXR to PPARγ, thereby adipogenesis is inhibited due to
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the blockade of expression of the PPARγ-induced adipocyte specific genes. However, in
our studies using a Nurr1 mutant that cannot heterodimerize with RXR, we found that
this mutant is still able to inhibit adipogenesis. This suggests that Nurr1 does not require
its interaction with RXR to inhibit adipocyte differentiation and RXR is not sequestrated.
Further, Nurr1 is typically considered as a positive transcription factor and has been
shown to regulate gene expression through its direct interaction with DNA (Davies et al.,
2005; Lammi et al., 2004; Sakurada et al., 1999). However, the recent findings
demonstrate that Nurr1 can also regulate gene expression without a direct interaction with
DNA by binding to the DNA bound NF-κB and subsequent recruitment of repressor
complex (Saijo et al., 2009). Hence, to delineate whether Nurr1 needs to bind to DNA or
not to inhibit adipogenesis, we used a mutant Nurr1 that cannot directly bind to DNA.
While the wild type Nurr1 inhibited adipogenesis, the Nurr1 mutant that cannot bind to
DNA was unable to inhibit adipogenesis. This provided evidence that Nurr1 must directly
bind to DNA in order to mediate its inhibitory effects on adipogenesis. However, the
genes directly regulated by Nurr1 during adipocyte differentiation are not known.
Collectively, our results provide evidence that while Nurr1 needs to directly bind to DNA
to inhibit adipogenesis, its heterodimerization with RXR is dispensable to mediate its
inhibitory effect on adipogenesis.
Having demonstrated that PGF2α induces Nurr1 expression through activation of
the calcineurin phosphatase, we focused on the mechanism by which the
PGF2α/calcineurin-signaling induces Nurr1 expression. In this respect, Nurr1 the
promoter contains a CRE consensus binding site and CREB has been shown to directly
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bind to the Nurr1 promoter, and induce Nurr1 expression in synoviocytes (McEvoy et al.,
2002). Further, inflammatory mediators such as PGE2, TNFα and IL-1β have also been
shown to induce Nurr1 expression through the CREB transcription factor (Ji et al., 2012;
McEvoy et al., 2002). Hence, we hypothesized that CREB might be involved in the
PGF2α-induced Nurr1 expression during adipogenesis. Using two different CREB
mutants that either block the endogenous CREB activity or cannot interact with its coactivator CRTC2, we found that CREB and its association with CRTC2 co-activator are
required for the PGF2α to induce Nurr1 expression during adipogenesis. While blocking
the calcineurin activity completely inhibits the PGF2α-induced Nurr1 expression, the two
different CREB mutants that we used in our studies were unable to completely abrogate
the PGF2α-induced Nurr1 expression. While the inadequate expression of these mutants
might be a possibility for this incomplete blocked of Nurr1 expression, it is also possible
that another transcription factor downstream of calcineurin might also be involved in
regulating Nurr1 expression. In this respect, NF-κB is known to be regulated by
calcineurin and has been shown to regulate Nurr1 expression in multiple cell types (Ji et
al., 2012; McEvoy et al., 2002). Hence, it is possible that Nurr1 expression is regulated
by PGF2α through activation of multiple transcription factors downstream of calcineurin.
Nevertheless, our findings demonstrate that CREB plays an important role in the PGF2αinduced Nurr1 expression during adipogenesis.
Having established that CREB is involved in the PGF2α-induced Nurr1
expression, we focused on the direct link between calcineurin and CREB in the regulation
of Nurr1 expression. It is well-known that CREB activity is regulated by CRTC co-
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activator proteins and importantly, these co-activators are dephosphorylated, and
activated by calcineurin phosphatase (Screaton et al., 2004). Further, CRTC2 is known to
selectively regulate CREB-induced Nurr1 expression in multiple cell types (Conkright et
al., 2003). In addition, we found that the CREB mutant that cannot interact with CRTC2
was able to significantly inhibit the PGF2α-induced Nurr1 expression, thus providing
initial evidence for the role of CRTC2 in the regulation of Nurr1 expression. Initially,
using YFP tagged CRTC2, we found that PGF2α induces a sustained activation and
nuclear translocation CRTC2, whereas this sustained activation was completely blocked
by pretreatment with calcineurin inhibitor, CsA. Thus, we found that the
PGF2α/calcineurin-signaling causes a sustained activation of the CRTC2 co-activator
during adipocyte differentiation. Interestingly, MDI treatment alone caused a transient
nuclear translocation of CRTC2, although the functional significance of this early
transient activation of CRTC2 is not known. Having established that CRTC2 is activated
by the PGF2α/calcineurin-signaling, we directly determined its role in Nurr1 expression
using a shRNA-mediated knockdown approach. We found that the depletion of the
endogenous CRTC proteins abrogated the PGF2α-induced Nurr1 expression, thereby
providing evidence that CRTC proteins are required for the PGF2α-induced Nurr1
expression during adipogenesis. Further, the selective activation of a tamoxifen inducible
form of a constitutively active CRTC2 was sufficient to induce Nurr1 expression and also
inhibits adipogenesis. This demonstrates that CRTC2 activation is sufficient to induce
Nurr1 expression and to inhibit adipogenesis. Collectively, we provide evidence that
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FIGURE 26. Schematic model showing that the PGF2α/calcineurin-signaling
pathway induces Nurr1 expression via CRTC2/CREB transcriptional complex to
inhibit adipogenesis.

The PGF2α/calcineurin-signaling pathway activates CRTC2 co-activator, which in turn
activates CREB transcription factor. The CRTC2/CREB transcriptional complex induces
Nurr1 expression, which inhibits adipocyte differentiation.
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CRTC proteins are required for the PGF2α-induced Nurr1 expression and CRTC2 is
sufficient to induce Nurr1 expression.
Though the selective activation of CRTC2 inhibits adipogenesis and CRTC2
plays a crucial role in mediating the inhibitory effects of PGF2α on adipocyte
differentiation, surprisingly, we observed that the stable depletion of CRTC expression
using the shRNA approach also blocks the normal adipocyte differentiation process.
When we determined the expression of key adipogenic transcription factors, we observed
that the expression of C/EBPδ, an early adipogenic transcription factor, is substantially
decreased in CRTC2 shRNA expressing cells. This is consistent with the previous finding
that CRTC2 is recruited to the C/EBPδ promoter to regulate CREB-dependent induction
of C/EBPδ (Hallenborg et al., 2012). Further, we also observed that CRTC2 is transiently
translocated into the nucleus in response to MDI (Fig. 22A, B), which correlated with the
time of expression of C/EBPδ expression during adipogenesis. Thus, we predict that the
early transient activation of CRTC2 positively regulates adipogenesis by potentially
regulating C/EBPδ expression. Conversely, the PGF2α/calcineurin-signaling causes a
sustained activation of CRTC2, resulting in the sustained expression of Nurr1 and
inhibition of adipocyte differentiation. Thus, it appears that the temporal activation of
CRTC2 is a switch between its positive and negative effects on adipocyte differentiation.
Collectively, we provide evidence that the PGF2α/calcineurin-signaling pathway
induces Nurr1 expression via activation of the CRTC/CREB transcriptional complex
during adipogenesis. Moreover, we demonstrate that the sustained expression of
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endogenous Nurr1 plays a role, atleast in part in mediating the inhibitory effects of the
PGF2α/calcineurin-signaling pathway on adipogenesis.

CHAPTER V
SUMMARY AND CONCLUDING COMMENTS
PGF2α has long been known to be a potent inhibitor of adipocyte differentiation in
vitro (Casimir et al., 1996; Miller et al., 1996). Moreover, recent studies have indicated
that PGF2α also functions as an endogenous negative regulator of adipogenesis and plays
an important role in the regulation of adipose tissue accumulation in vivo, where it
appears to oppose the development of obesity and its associated co-morbidities (Volat et
al., 2012). Given this clear critical physiological role of PGF2α in the negative regulation
of adipose tissue development in vivo, it is of considerable interest to understand the
underlying molecular mechanisms by which PGF2α regulates the adipogenic process. In
this regard, our previous studies have demonstrated that PGF2α inhibits adipogenesis
through a signaling pathway involving the activation of the Gαq-coupled prostanoid FP
receptor, a subsequent increase in the intracellular calcium and the activation of the
calcium-dependent phosphatase, calcineurin (Liu and Clipstone, 2007). In this
dissertation, we have now extended these prior studies and provide evidence that the
PGF2α/calcineurin-signaling pathway acts to inhibit adipogenesis by inducing the
expression of the IL-11 cytokine and the Nurr1 nuclear hormone receptor. In the case of
IL-11, we demonstrate that IL-11 functions in an autocrine/paracrine fashion and induces
a gp130 co-receptor-dependent activation of the STAT1 transcription factor, which we
136
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show is essential for mediating the inhibitory effects of PGF2α on adipogenesis. In the
case of Nurr1, we show that Nurr1 plays an important role in mediating the inhibitory
effects of PGF2α on adipogenesis and further, demonstrate that PGF2α induces a
calcineurin-dependent, sustained activation and nuclear translocation of CRTC proteins,
which then interact with CREB to drive Nurr1 expression. Collectively, our studies
provide evidence that the PGF2α/calcineurin-signaling pathway inhibits adipogenesis
through

two

independent

signaling

mechanisms:

IL-11/gp130/STAT1- and CRTC/CREB/Nurr1-signaling.
Although we provide evidence that IL-11 and Nurr1 each independently mediate
the inhibitory effects of PGF2α on adipogenesis, it is noteworthy that neither depletion of
IL-11 and STAT1 using shRNAs, nor blocking the endogenous Nurr1 activity with a
dominant-negative Nurr1 were able to completely rescue the differentiation of 3T3-L1
preadipocytes in the presence of PGF2α. These findings contrast with our prior results
demonstrating that the inhibition of calcineurin is able to essentially fully abrogate the
anti-adipogenic effects of PGF2α (Liu and Clipstone, 2007). While in part these
differences may be explained by incomplete knockdown of STAT1 and IL-11 or
incomplete expression of dominant-negative Nurr1, as well as potentially the non-cell
autonomous actions of the IL-11 cytokine, we feel that it is likely that both the IL-11 and
Nurr1 pathways function together collaboratively to mediate the inhibitory effects of
PGF2α on adipogenesis. Further, we have previously reported that activation of the
PGF2α/calcineurin-signaling pathway in differentiating 3T3-L1 preadipocytes also
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induces the HIF-1-dependent expression of DEC1 (Liu and Clipstone, 2008), a
transcriptional repressor that is known to inhibit adipocyte differentiation by preventing
the expression of PPARγ2 (Yun et al., 2002). Hence, it appears that calcineurin functions
as a central node for mediating the inhibitory effects of PGF2α by activating multiple
signaling pathways that ultimately collaborate together to effectively inhibit the
adipogenic process.
While we demonstrate that exogenous PGF2α acts through calcineurin to inhibit
adipogenesis (Liu and Clipstone, 2007), our previous studies showed that blocking the
endogenous calcineurin activity enhanced the adipogenic potential of preadipocytes and
thus, suggested that calcineurin acts as an endogenous negative regulator of adipocyte
differentiation (Neal and Clipstone, 2002). Likewise, PGF2α is transiently synthesized
during the very early stage of adipogenesis (Fujimori et al., 2010a) and inhibiting its
endogenous synthesis has been shown to enhance adipose tissue development in vivo
(Volat et al., 2012). Thus, PGF2α also functions as endogenous inhibitor of adipose
tissue development. Hence, it is tempting to speculate that the endogenous inhibitory
effect of PGF2α is also mediated through calcineurin-dependent activation of the
signaling pathways described in this dissertation. In this regard, we find an endogenous,
calcineurin-dependent secretion of IL-11 during the early stages of normal adipogenesis.
Further, inhibiting IL-11 signaling using either a dominant-negative gp130 or depleting
its downstream effector STAT1, enhances the efficiency of preadipocytes to differentiate
into mature adipocytes. Hence, we predict that the endogenous inhibitory effect of the
PGF2α/calcineurin-signaling pathway is, at least in part, mediated through activation of
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an autocrine/paracrine feedback loop involving IL-11/gp130/STAT1-signaling. In
addition, we find that the PGF2α/calcineurin-signaling also activates other signaling
pathways including the expression Nurr1 and DEC1, which mediate the inhibitory effects
of exogenous PGF2α. Although we do not currently have any direct evidence to support
their role in mediating the inhibitory effects of endogenous PGF2α on adipogenesis, we
cannot exclude their potential endogenous role and further studies are needed.
Multiple lines of evidence show that adipose tissue expansion through de novo
generation of new adipocytes play a protective role from the development of obesityassociated complications by increasing the lipid buffering capacity of adipose tissue and
preventing lipotoxicity (Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). In this
regard, PGF2α is known to restrict adipose tissue expansion in vivo, which results in the
development of obesity-associated consequences such as insulin resistance (Volat et al.,
2012). In our studies, we find that calcineurin functions as a central node to mediate the
inhibitory effects of PGF2α on adipogenesis. Hence, it is tempting to ask whether
inhibiting calcineurin activity in vivo specifically in preadipocytes or adipose tissue with
clinically available calcineurin inhibitors would enhance adipogenesis, thereby increasing
the lipid buffering capacity and providing beneficial effects to obese patients. In this
respect, organ transplanted patients who are treated with calcineurin inhibitors to prevent
graft rejection are known to develop obesity (LaGuardia and Zhang, 2013). Given our
finding that blocking endogenous calcineurin activity enhances adipogenesis (Neal and
Clipstone, 2002), it is possible that these patients develop excessive adipose tissue due to
increased number of adipocytes. While this effect seems to be beneficial to prevent
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lipotoxicity, calcineurin activity is required for the growth and proliferation of insulin
secreting pancreatic β-cells (Heit et al., 2006) and the prolonged use of calcineurin
inhibitors leads to the development of type 2 diabetes due to dysfunction of pancreatic βcells (Drachenberg et al., 1999; Weir and Fink, 1999). Hence, while the prolonged oral
and parentral administration of calcineurin inhibitors is more deleterious than beneficial,
the selective tissue specific delivery of these drugs to adipose tissue might have better
effect with fewer side effects by enhancing adipogenesis and improving metabolic
complications in obese patients. Alternatively, other signaling pathways described in this
dissertation that are activated downstream of calcineurin could be used as a potential
therapeutic target to enhance the adipogenesis.
Finally, while our studies demonstrate that STAT1 and Nurr1 proteins function as
downstream effectors of the PGF2α/calcineurin-signaling, the precise molecular
mechanism by which they inhibit adipocyte differentiation is not known. Since, these two
proteins are known to directly regulate gene expression both positively and negatively
(Furukawa et al., 2009; Jacobs et al., 2009; Kim et al., 2013; Liu et al., 2008; Ramana et
al., 2000; Sirin et al., 2010), we predict that they likely inhibit adipogenesis by
influencing the expression of genes involved in the adipogenic process. In a simple
model, both STAT1 and Nurr1 might directly repress the expression of the key
adipogenic transcription factor, PPARγ, thereby inhibiting adipogenesis. In this respect,
STAT1 has previously been shown to directly bind to the PPARγ promoter in vitro
(Hogan and Stephens, 2001). Further, STAT1 is known to interact with co-repressors and
inhibit gene expression (Kamitani et al., 2008; Liu et al., 2001). Hence, we predict that
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STAT1 could potentially directly bind to the PPARγ promoter, recruit transcriptional corepressors and inhibit PPARγ expression. In the case of Nurr1, another related nuclear
hormone receptor COUP-TFII has been shown to directly bind to the PPARγ locus,
where it recruits co-repressor complexes and inhibits adipogenesis (Okamura et al.,
2009). Further, Nurr1 has also been shown to interact with co-repressors and inhibit gene
expression (Kim et al., 2013; Saijo et al., 2009). Hence, similar to STAT1, it is possible
that Nurr1 could directly bind to the PPARγ promoter, recruit co-repressor and inhibit the
expression of PPARγ. In contrast to directly inhibiting the expression of key adipogenic
transcription factors, it is possible that both STAT1 and Nurr1 might indirectly inhibit
adipogenesis by increasing the expression of a gene(s) that itself directly inhibits the
expression of key adipogenic transcription factors and thereby, inhibits adipogenesis.
However, our microarray analysis did not identify any potential candidate genes. Another
possibility is that both STAT1 and Nurr1 could upregulate the expression of a
microRNA(s) that inhibits the expression of the key adipogenic transcription factors,
PPARγ or C/EBPα. In this regard, it is interesting to note that STAT1 has recently been
implicated in promoting the expression of microRNA-27a (Wang et al., 2010), a
mircoRNA that has previously been shown to negatively regulate the expression of the
PPARγ mRNA and block adipogenesis when overexpressed in 3T3-L1 preadipocytes
(Kim et al., 2010). However, whether this microRNA is induced by STAT1 in response
to PGF2α during adipogenesis is not known and thus, requires further studies. While
there are multiple possible mechanisms by which STAT1 and Nurr1 could potentially
inhibit adipogenesis, the critical genes involved have not been identified.
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FIGURE 27. Schematic model showing the signaling pathways involved in mediating
the inhibitory effects of PGF2α on adipogenesis.
PGF2α activates the calcium-dependent phosphatase calcineurin via activation of Gαq
coupled FP prostanoid receptor. Then, the PGF2α/calcineurin-signaling pathway induces
the expression of the IL-11 cytokine, which activates STAT1 transcription factor via
gp130 co-activator to inhibit adipogenesis. Further, the PGF2α/calcineurin-signaling
pathway also activates CRTC/CREB transcriptional complex and subsequently, induces
the expression of the orphan nuclear hormone receptor, Nurr1 to inhibit adipocyte
differentiation. Collectively, both IL-11 and Nurr1 function downstream of the
PGF2α/calcineurin-signaling pathway to exert its inhibitory effects on adipogenesis.
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The identification of the direct in vivo targets of Nurr1 and STAT1 will require the use of
modern, high throughput techniques such as ChIP-sequencing.
In summary, the work of this dissertation has afforded novel insights into the
molecular mechanisms underlying the anti-adipogenic effects of the PGF2α/calcineurinsignaling pathway and has provided evidence for the potential role of the IL-11 cytokine
and the Nurr1 orphan nuclear hormone receptor in mediating the inhibitory effects of
PGF2α on adipocyte differentiation. Thus, our studies significantly expanded our
understanding concerning the molecular mechanisms involved in the PGF2α-mediated
inhibition of adipogenesis.
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